




















































INTRODUCTION'The! number! of! protons! found! in! an! atom's! nucleus! (atomic! number),! confers! a!specific! position! inside! the!periodic! table! thus! characterizes!univocally! every! element.!All!atoms! of! the! same! element! have! the! same! atomic! number! but! may! differ! in! the! mass!number!(number!of!nucleons).!When!element's!atoms!have!different!numbers!of!neutrons!they!are!named!isotopes!of!that!element.!Based! on! the! stability! of! the! nucleus,! isotopes! can! be! stable! or! radioactive.! The!stable! isotopes!have!a!stable!combination!of!protons!and!neutrons!thus!they!do!not!decay!and!they!are!considered!to!be!safe.!Instead!radioactive!isotopes!undergo!decay,!and!during!this!process!they!can!emit!different!type!of!rays!(alpha,!beta!or!gamma).!Since!atomic!mass!bears! influence! reactivity,! isotopes!of! the! same!element!exhibit!nearly! identical! chemical! behaviour.! However,! their! mass! difference! can! lead! to! the!discrimination!from!one!to!another!isotope!by!some!physical!or!chemical!processes.!As!a!consequence!of!this!“being&similar&but&not&identical”,!isotopes!are!important!tools!with!a!unique!number!of!applications.!!!
ISOTOPES'IN'CLINICAL'PRACTICE'AND'IN'LIFE'SCIENCE'RESEARCH'Due! to! their! safety,! stable! isotopes!are!used!both! in! clinical!practice,! as!diagnostic!tools,!and!in!research!to!study!metabolic!processes!in&vivo.!In!these!fields!when!we!talk!about!stable!isotopes!we!are!not!referring!to!a!specific!isotope!of!an!element,!rather!to!a!molecule!in!which!one!or!more!atoms!have!been!replaced!by!the!heavier!isotopes.!!The!most!known!example!of!isotope!administered!in!clinical!practice!is!undoubtedly!13CFurea.! The! 13CFurea! breath! test! allows! for! a! noninvasively! detection! of! Helicobacter&
pylori1.!Helicobacter&pylori! is!able!to!survive! in!the!stomach!because! it!produces!urease!an!enzyme! that! cleavages!urea!and! locally! lowers! the!pH!value.!After! the!administration!of! a!dose!of! 13CFurea,!Helicobacter&pylori&produces!ammonia!and! 13CO2!that!appears!only! in! the!expired! CO2! of! patients! positively! affected! by! the! infection.! The! result! of! the! test! is!
!!
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considered! to!be!positive!when! the!amount!of! 13CO2! is! significantly!higher! than! the! levels!normally!observed!in!the!population.!13C!breath!tests!are!often!used!in!clinical!practice,!especially!in!the!field!of!gastroenterology!because!of!their!being!nonFinvasive,!safe,!simple,!and!effective.!All!these!tests!are!based!on!the!same!principle!of!13CFurea!breath!test,!since!they!involve!the!measurement!of!the!13C/12C!ratio! in! breath! CO2! after! ingestion! of! a! nutrient,!meal,! or! other! substrate! containing! 13C2.!Because! the! increased! enrichment! in! breath! 13CO2! should! reflect! digestion,! absorption,!metabolism,!and!oxidation!rate!of!the!substrate!it!is!possible!to!obtain!specific!information!about! different! diseases.! Examples! of! conditions! that! can! be! investigated! by! the! use! of!breath!tests!are:!malabsorption!and!pancreatic!function,!liver!function!and!disease,!bacterial!overgrowth,!maldigestion!and!gastroparesis3.!!Water! labelled! with! 2H! or! 18O! represents! another! example! of! isotopes! used! in! clinical!practice:!by!its!administration!is!possible!to!measure!total!body!water,!water!turnover!and!total!daily!energy!expenditure4.!! Stable! isotopes! labelled!molecules! are! very! important! also! in! life! science! research!where! they! play! pivotal! roles! in! metabolic! studies.! Virtually,! any! metabolic! process!involving! proteins,! lipids,! or! carbohydrates! can! be! studied! using!molecules! labelled! with!stable! isotopes!of! carbon! (13C),!hydrogen! (2H!deuterium),!nitrogen! (15N),!or!oxygen! (180)5.!The!replacement!of!atoms!with!the!heavier!isotopes!allows!to!discriminate,!to!trace,!and!to!detect! both! the!parental! compound!of! interest! and! its!metabolites! from! the!ones! that! are!physiologically!found!in!the!living!organisms.!Because!of!their!ability!to!trace!the!metabolic!pathway!of!the!molecule!of!interest!these!compounds!are!defined!as!tracers.!!




STUDY'DESIGN'OPTIONS'IN'STABLE'ISOTOPES'STUDIES''There! are! two! types! of! metabolic! studies:! the! ones! that! study! the! tracer! itself!without!considering!metabolic!transformations,!and!those!that!study!the!conversion!of!the!tracer!as!a!precursor!into!one!or!more!products5.!The!type!of!study!to!undertake!depends!on!the!questions!needed!to!be!addressed.!Beside! the! type! of! metabolic! study! there! are! also! different! experimental! approaches!available.! The! identification! of! the! best! study! design! to! use! depends! on! the! information!needed,! sensitivity! and! accuracy! requirements,! availability! of! labelled! tracers! and! finally!analytical!equipment!8.!Ideally! tracers!can!be! introduced!by!all!routes!of!administration!(for!example!oral,!enteral,! endotracheal! or! intravenous);! by! single! dose! (bolus),! by! multiple! doses! or! by!constant! infusion.!Generally,! the! last! two!approaches! are! required! in!kinetic! studies! since!only! after! achieving! the! isotopic! steady! state! some! assumption! and! calculations! can! be!made.! In!singleFlabelledFexperimental!design!only!a!tracer!molecule!is!administered!while!the!multiple–labelled!design!consists! in! the!administration!of!a!mixture!containing! two!or!more! tracers.! The! advantage! of! the!multiple–labelled! design! is! particularly! evident! in! the!metabolic! studies! of! related! compounds,! not! only! because! more! information! can! be!obtained!for!nearly!the!same!effort!but!also!because!the!metabolic!fate!of!different!related!compounds! can! be! directly! compared! in! the! same! subjects,! reducing! interpretation!problems!due!to!subject!variability8.!Finally,! another! important! issue! in! study! design! is! the! identification! of! how! the!molecule!has!to!be!labelled!in!order!to!provide!the!information!needed.!For!example,!if!the!purpose! of! our! research! is! to! study! the! conversion! rate! of! linoleic! acid! (18:2nF6)! into!arachidonic!acid!(20:4nF6)!we!will!administer!a!single!oral!dose!of!UF13C18:2!nF6!as!a! free!fatty!acid;!conversely!if!we!are!interested!in!studying!how!triglyceride!structure!impacts!on!fatty!acids!absorption!we!need!to!label!differently!the!fatty!acids!esterified!to!the!backbone!of!glycerol9.!Tracers! labelled! with! stable! isotopes! used! in! metabolic! studies! are! obtained! by!chemical! synthesis.! Cost! of! isotopes! is! one! of! the! factors! that! must! be! considered! when!calculating! the! amount! of! tracer! to! use! in& vivo! experiment.! Usually! there’s! a! tradeoff!between!the!lowest!dose!to!administer!and!the!minimum!enrichment!that!has!to!be!reached,!
!!
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in!order! to!obtain! an!acceptable! accuracy! in! the! results,!which!ultimately!depends!on! the!analytical!equipment.!!
STABLE'ISOTOPE'NATURAL'ABUNDANCE'The! “natural! carbon! 13! C! diet! approach”! or! “stable! isotope! natural! abundance!approach”!allows!to!use,!as!tracers,!molecules!characterized!by!a!13C!content!that!is!different!from! the! one! usually! observed! in! the! population.! These! tracers! are! not! produced! by!chemical!synthesis!but!can!be!obtained!by!an!accurate!selection!of!nutrient!sources.!In!fact!the! method! is! based! on! the! measurement! of! the! natural! variation! in! the! 13C! content! of!selected!nutrients.!Above! it! has! been! stated! that,! due! to! the! different! mass,! isotopes! can! be!discriminated!by!some!physical!or!chemical!processes.!Processes!that!impact!on!the!relative!abundance! of! isotopes! are! known! as! “isotope& fractionation”.! Fractionation! can! occur,! for!example,!during!phase!changes.!The!process!of!evaporation!enriches!the!liquid!water!of!the!heavier!isotopes!(18O!and!2H)!while!the!lighter!isotopes!(16O!and!1H)!tend!toward!the!vapour!phase.!During!condensation!the!heavier!isotopes!are!the!first!to!condense!while!the!lighters!tend!to!remain!into!the!vapour!phase.!This!explains!why!snow!falling!at!the!poles!is!depleted!in!2H!and!18O!content!with!respect!to!rainfall!at!the!equator.!Fractionation! can! also! occur! during! biological! processes,! for! example! during!photosynthesis.! Because! of! small! differences! imparted! by! the! different! mass,! plants!discriminate!against!13C!10.!There! are! three! types! of! plants:! C3,! C4! and! CAM!plants.! C3! plants! use! the! CalvinFBenson!photosynthetic! cycle! and! they! fix! CO2! by! the! action! of! ribulose! phosphate! carboxylase.!Carboxylation! step! shows! great! fractionation! and! explains! the! very! low! content! of! 13C!observed!in!these!plants!(δ!13C!varies!from!F22!to!F35!0/00).!Examples!of!C3!plants!are!wheat,!rice,!and!rye.!C4!plants!use!the!Hatch!–Slack!photosynthetic!cycle:!CO2!is!taken!up!through!phosphoenolpyruvate! carboxylase! and! converted! into!malate! or! aspartate!which! are! then!cleavage!again! in!CO2!that! is! finally! taken!up!by!ribulose!phosphate!carboxylase.!Since!the!first!process!does!not!show!a!strong!fractionation!effect!this!plants!have!a!higher!content!of!13C!compared!to!C3!plants!(δ!13C!varies!from!F8!to!F20!0/00).!Examples!of!C4!plants!are!sugar!cane,! corn,! and! tropical! grasses! plants.! The! third! type! of! plants,! to! whom! pineapple! and!cactus!belong,!use!the!Crassulacean!acid!metabolism!(CAM).!CAM!plants!during!night!act!as!C4!plants!while!during!the!afternoon!like!C3!plants,!their!content!of!13C!allows!to!distinguish!them!from!C3!plants!(δ!13C!varies!from!F10!to!F20!0/00)!while!the!distinction!from!C4!must!be!made!by!other!measurements.!
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Because! animals! can! incorporate! carbon! only! ingesting! vegetables! or! meat! the!amount!of! 13C! found! in! their!body,! as! in! the!expired!CO2,!will!mirror! the! isotope! ratios!of!their! food!sources.!European!diets!are! richer! in!C3!plants!while!North!American!diets!are!richer! in! C4! plants.! As! a! consequence! European! people! have! 13C/12C! ratios! similar! to! C3!plants!and!lower!ratios!compared!to!people!living!in!North!America11.!!
!
'
Figure'1.'Typical!examples!of!natural!δ!13C!values.!!From!MeierFAugenstein!et&al.12!! The! stable! isotope!natural! abundance!approach! consists! in! administering!a!nutrient!which!13C/12C!ratio!differs!from!the!one!usually!found!in!the!population!in!order!to!study!its!metabolic! fate.! In! European! population! nutrients! from! C4! plants! can! be! used! as! natural!tracers,!since!after!their!administration!a!change!in!the!isotopic!enrichment!mean!value!of!the!nutrient!can!be!observed.!This!approach!has!been!used!in!humans!for!the!first!time!in!1995!to!estimate!arachidonic!acid!synthesis! in!full! term!neonates13.!Our!research!group!in!2007! published! a! study! using! the! same! approach! to! estimate! linoleic! acid! and! α! Flinoleic!conversion!into!their!long!chain!polyunsaturated!fatty!acids!metabolites14!!Advantages!of!stable!isotope!natural!abundance!approach!are!first!of!all!economic,!since!no!isotopes!have! to!be! synthesised,!moreover! they! are! extremely! safe.!Major! limitations! are:!!!!
!!
! 10!
i)! impossibility! to! trace! all! the! metabolic! pathways! and! ii)! necessity! of! analytical!instrumentation!with!a!high!accuracy!in!measuring!the!13C/12C!ratio.!!
MASS'SPECTROMETRY!With! modern! analytical! techniques,! tracers! can! consecutively! be! detected! either!unchanged! or! after! conversion! into! their! metabolites.! Mass! spectrometry! (MS)! is! the!analytical!method!most!used! in!stable! isotope! labelling!studies.!Because!MS!separates!and!quantifies! ions! on! the! base! of! their! massFtoFcharge! ratio! (m/z)! by! this! technique! it! is!possible!to!discriminate!between!isotopes!found!in!simple!and!complex!mixtures.!!The!application!of!MS!to!biology!started!in!the!1940s,!when!heavy!stable!isotopes!were!used!as! tracers! to! study!processes! such!as!CO2!production! in!animals15.!Nowadays!MS! shows!a!wide! range! of! applications! in! several! fields! like! proteomics,! genomics,! drug! discovery,!environment,!forensic!and!pharmacology.!!












' Long! chain! polyunsaturated! fatty! acids! (LCFPUFAs)! are! fatty! acids! (FAs)!characterized!by!a!chain!of!at!least!20!carbons!and!three,!or!more,!double!bonds.!Depending!on!the!position!of!the!first!double!bond!from!the!methyl!end!of!the!carbon!chain,!LCFPUFAs!can!be!divided!in!two!main!classes:!nF3!and!nF6i.!Despite! they! can! act! as! an! energy! source,! like! all! the! FAs,! their! main! functions! are,!undoubtedly,! metabolic! and! structural.! LCFPUFAs! are! precursors! of! lipid! mediators,!regulators! of! physiological! functions! and! inflammatory! processes,! and! they! are! also!important! components! of! cell! membrane! phospholipids! (PLs),! maintaining! membranes!characteristic!fluidity,!permeability!and!conformation.!Among! LCFPUFAs! arachidonic! (ARA;! 20:4nF6),! eicosapentaenoic! (EPA;! 20:5nF3)! and!docosahexaenoic!acid!(DHA;!22:6nF3)!are!of!particular!biological!interest.!!




In!the!endoplasmatic!reticulum,!via!the!mammalian!pathway!of!nF6!and!nF3,!LA!and!ALA!can!then! be! converted,! respectively,! in! ARA! and! EPA! by! consecutive! desaturation! and! chain!elongation! steps18.! Further! steps! and! a! compartmental! translocation! to! peroxisomes! are!required!to!obtain!DHA!from!EPA18.!!
!!
Figure1.!Metabolic!pathway!of!nF3!and!nF6!LCFPUFAs!in!humans.!Adapted!from!Giltay!et&al.19.!!The!sharing!of!the!same!enzymes!causes!a!competition!between!LA!and!ALA!metabolism.!As!a!result,! in!the!western!diets,!where!consumption!of!LA!is!much!higher!than!that!of!ALA20,!conversion!of!the!nF6!PUFAs!predominates!on!the!nF3!series.!By! the! administration! of! EFAs,! labelled! with! stable! isotopes,! several! studies!investigated!human!subjects’!ability!to!convert!them!into!LCFPUFAs!products21–26.!Approximately!22F33%!of!the!administered!dose!of!ALA!was!used!as!an!energy!source!and!ßFoxidised! to!CO221,22,! and! less! than!10%!was!used! for!DHA!synthesis21,22,25.!These! studies!pointed! out! how,! in! human! subjects,! gender! appears! to! be! a! strong! determinant! in! DHA!synthesis!with!women!having! a!much! greater! ability! in! the! bioconversion! of!ALA! to!DHA!compared!to!men21,22,27,!probably!because!of!the!effects!of!estrogens22,28.!Studies!performed!in!newborns!showed!that!both!term!and!preFterm!newborns!are!capable!of! synthesizing! LCFPUFAs! from! their! 18Fcarbon! precursors23,26! and! that! infants! with!intrauterine!growth!restriction!(IUGR)!have!a!less!active!DHA!formation!than!those!who!are!
!!
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appropriate!for!gestational!age24.!In!preFterm!newborns!ARA!synthesis!at!1,!3,!and!7!months!of! age! was! found! to! be! significantly! greater! than! DHA! synthesis! and! both! LCFPUFAs!synthesis!decreased!significantly!with!time14.!In! the! last! decade! a! number! of! studies! have! investigated! the! association! between!variants! in! the! fatty! acid! desaturase! encoding! genes! (FADS)! and! the! efficiency! of! these!enzymes! in! the! production! of! LCFPUFAs! from! their! precursors29–33.! The! higher! levels! of!substrates!and!lower!levels!of!desaturase!products!found!in!the!carriers!of!the!minor!allele!suggested!a!decline!in!desaturase!activity!because!of!the!polymorphism.!!
BIOLOGICAL'ROLE'OF'LCLPUFAs'LCFPUFAs! are! the! metabolic! precursors! of! several! lipids! mediators! that! play! key!roles!in!inflammation,!in!physiologic!and!pathologic!processes.!Acute! inflammation!response!can!be!divided! in!2!phases:! initiation!and!resolution.!Eicosanoids,!such!as!prostanoids!and!leukotrienes,!are!potent!proFinflammatory!mediators!derived!from!the!metabolism!of!ARA!by!the!action,!respectively,!of!cyclooxygenaseF2!and!5Flipoxygenase.!Since!they!allow!the!recruitment!of!neutrophils!and!their!homing!at!the!site!of!inflammation! they! are! of! particular! importance! in! the! initial! response! phase.! During! the!course! of! inflammation! prostaglandin! E2! switches! eicosanoid! biosynthesis! from!predominantly!proFinflammatory!arachidonateFderived!mediators!to!the!antiFinflammatory!and!proFresolution!ones,!namely!lipoxins!(LXs)34.!LPXs,!generated!from!ARA!by!the!action!of!15Flipoxygenase,! are! important! in! limiting! the! inflammation! cascade,! since! they! inhibit!neutrophils! recruitment!and!promote!phagocytosis!of!apoptotic!neutrophils!by!monocyteFderived! macrophages35.! The! discovery! of! LXs! and! their! antiFinflammatory! activity!“shattered!the!dogma”!that!all!ARAFderived!mediators!are!solely!proFinflammatory36.!During! the! selfFlimited! resolution! phase! several! lipid! mediators! from! nF3! LCFPUFAs! are!biosynthesized!by!new!pathways.!Resolvins,!protectins!and,!the!last!discovered,!maresines,!collectively! named! specialized! proFresolving!mediators! (SPM)! represent! these! novel! proFresolving!local!mediators!that!are!characterized,!in&vivo,!by!antiFinflammatory!properties.!The! discovery! of! SPM! was! the! evidence! for! considering:! i)! resolution! of! selfFlimited!inflammation!not!only!a!passive!process!but!an!active!programmed!response!turned!on!by!neutrophils,! and! ii)! antiFinflammatory! effects! of! nF3! LCFPUFAs! not! only! due! to! the!competition!with!ARA,!in!preventing!proFinflammatory!eicosanoids!biosynthesis,!but!in!the!production!of!active!proFresolving!lipid!mediators37.!Eicosanoids! are! reported! to! affect! and! regulate! the! physiology! of! cardiovascular!system.!ARA!is!the!precursor!of!prostaglandin!and!thromboxane!2Fseries,!the!first!has!a!proFarrhythmic!effect!while!the!second!is!a!potent!platelet!activator!and!a!vasoconstrictor!agent.!
!!
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DHA' SUPPLEMENTATION' DURING' PREGNANCY:' EFFECTS' ON' FETAL' DEVELOPMENT'
AND'PREGNANCY'OUTCOMES'During!the!third!trimester!of!pregnancy!and!during!the!first!month!of!postnatal!life!considerable! amounts! of! DHA! accumulate! in! retinal! photoreceptors! and! neuronal! cell!membranes.! Accumulation! then! continues! up! until! the! first! 24! months! of! life,! even! if! at!lower!rates.!An!adequate!supply,!especially!during!the!embryological!organogenesis!and!the!first! months! of! postFnatal! life,! seems! than! to! be! of! critical! importance! for! the! normal!neurological!and!visual!development.!!In!the! last!decade,!after!observational!studies!suggested!the!existence!of!a!positive!association! between! oily! fish! consumption! during! pregnancy! and! cognitive! and! visual!abilities!of!the!offspring,!several!randomized!controlled!trials!(RCTs)!were!performed.!!Gould!et&al.!in!2013!published!the!first!comprehensive!systematic!review!and!metaFanalysis,!including!published!and!unpublished!trials,!of!nF3!LCFPUFAs!supplementation!in!pregnancy!with! cognitive!and!visual!outcomes42.!The! review!highlighted! that!many!of! the!RCTs!have!several!methodological! limitations!such!as!small!sample!size,!systematic!bias,!poor!quality!and!lack!of!data;!moreover,!in!some!trials!supplementation!took!place!during!pregnancy!and!lactation,! which!made! difficult! to! determine! the! period! during! which! supplementation! is!effective!if!a!benefit!is!found.!The!authors!combined!in!a!metaFanalysis!the!data!relative!to!cognitive!development.!No!differences!were!observed!between! infants,! toddlers! or! school!age!children!of!supplemented!and!control!groups.!Only!in!the!preschool!children!group!(2F5!years),!after!supplementation!during!pregnancy!and!lactation,!development!standard!score!and!intelligent!quotient!were!found!to!be!higher,!despite!this!effect!was!from!two!trials!with!a! high! risk! of! bias.! As! far! as! the! visual! development! no! metaFanalysis! was! performed!because! of! the! use! of! different! tests! and! ages! at! assessment.! The! authors! conclude! that!evidence!does!not!support!or!refute!the!hypothesis!that!nF3!LCFPUFAs!supplementation!in!pregnancy!improves!child!cognitive!or!visual!development.!Effects! of! nF3! LCFPUFAs! supplementation! on! gestation! length! and! preterm! birth!rates!have!been!investigated!too.!Three!metaFanalysis!of!RCTs!found!that!gestational!age!at!delivery!was!significantly!higher!in! the! intervention! group! supplemented! with! nF3! LCFPUFA43–45.! Szajeska! et& al.! found! a!weighted!mean!difference!of!1.57!days! (95%!CI:!0.35F2.78)43,!Makrides!et&al.! of!2.55!days!(95%!CI:!1.03F4.07)44!and!Salvig!et&al.!of!4.5!days! (95%!CI:!2.3F6.8)45.!An! increase! in!birth!weight! was! reported! too44,45.! Larqué! et& al.! in! a! systematic! review! suggested! that! the!
!!
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somewhat!higher!birth!weight!reported!in!RCTs,!for!supplemented!pregnancy,!was!probably!due!to!the!greater!length!of!these!pregnancies,!since!in!one!of!the!RCTs!no!differences!were!observed!anymore!when!using!the!gestational!age!as!covariable46.!More!controversial!are!the!effects!of!supplementation!in!reducing!the!risk!of!preterm!birth.!A!recent!systematic!review!and!metaFanalysis!conclude!that!nF3!LCFPUFAs!supplementation!during! pregnancy! does! not! reduce! the! incidence! of! preterm! birth! or! improve! neonatal!outcome! measured! as! birth! weight,! neonatal! intensive! care! unit! admission,! necrotizing!enterocolitis,!or!sepsis47.!Effects! of! supplementation! during! pregnancy! on! allergic! diseases! in! newborns,!preeclampsia,!maternal!and!postpartum!depression!were!addressed!too.!Data!from!reviews!and!metaFanalysis!do!not!find!differences!in!preFeclampsia!rates!43,44,48!or!advantages!in!the!incidence!of!maternal!and!postpartum!depression!49.!Global! recommendations! for! EPA! and! DHA! intake,! revised! in! 2014,! suggest! that!pregnant!and!lactating!woman!should!introduce!at!least!200!mg!DHA/day.!As!suggested!by!Larqué!et&al.!nF3!LCFPUFA!supplementation!may!not!yield!any!measurable!benefit!but!very!low!intakes!could!result!in!loss!of!function!that!could!be!of!major!importance!in!prematurely!born!babies46.!In!a!randomized!multicenter!trial,!fish!oil!supplementation!during!pregnancy!from! gestation! week! 22! until! delivery,! beside! improving! fetal! nF3! LCFPUFAs! status,! was!found! to! attenuate! depletion! of! maternal! stores50.! As! observed! by! Hanebutt! et& al.51! DHA!supplementation!counteracts!the!depletion!of!maternal!DHA!stores!during!the!last!trimester!meeting!the!increased!fetal!needs!that!peak!when!human!brain!growth!spurts.!!
FAs'TRANSPORT'ACROSS'HUMAN'PLACENTA'FAs! are! transported! across! placenta! only! in! form! of! nonFesterified! fatty! acids!(NEFAs).! NEFAs! taken! up! by! the! placenta! are! derived! from! maternal! circulating! NEFAs,!bound!to!albumin,!and!from!triglycerides!(TG)iii.!!NEFAs! can! cross! lipid! bilayers! by! simple! diffusion! or! by! saturable! proteinFmediated!transport.! Proteins! identified! in! NEFAs’! transfer! across! placenta! are:! plasma! membrane!fatty! acid! binding! protein! (PFFABPpm)! and! fatty! acid! transfer! proteins! (FAT/CD36! and!FATP).!The!existence!of!this!complex!and!specific!FAsFtransport!system!has!been!proposed!to! be! crucial! in! facilitating! the! preferential! transport! of!maternal! plasma! FAs! so! that,! the!requirements!of!the!fetus!can!be!met51.!Once! inside! the! cytosol! of! the! syncytiotrophoblast! NEFAs! can! be! differently! routed.! They!can! bind! the! intracellular! fatty! acid! binding! proteins! (FABS)! and! be! translocated,! across!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!iiiThe!presence,!in!human!placenta,!of!binding!sites!for!lipoproteins!and!the!lipoprotein!lipase!activity,!which!hydrolyzes!lipid!esters,!allow!the!utilization!of!maternal!TG,!as!sources!of!NEFAs.!
!!
! 19!
basal!membrane,!to!fetal!circulation!by!the!action!of!FAT/CD36!or!FATP.!NEFAs!can!also!be!reFesterified! and! deposited! as! TG! for! later! release,! or! used! to! produce! energy,! via! ßFoxidation,!or!even!to!synthesize!eicosanoids.!Finally!they!can!also!modulate!gene!expression!by!the!activation!of!nuclear!transcription!factors.!!
!!
Figure'2.!Model!of!placental!fatty!acid!transport.!LP,!lipoprotein;!LPL,!lipoprotein!lipase;!NEFA,!nonFesterified!fatty!acid;!FATP,!fatty!acid! transport! protein;! FAT,! fatty! acid! translocase;! PFFABPpm,! placental! plasma!membrane! fatty!acid!binding!protein;!LFFABP,! liverFfatty!acid!binding!protein;!HFFABP,! heartFfatty! acid! binding! protein;! PPAR,! peroxisome! proliferator! activated!receptor;!RXR,!retinoid!X!receptor.!From!Hanebutt!et&al51.!! Several!studies! found!significantly!higher!percentages!of!ARA!and!DHA!(and! lower!LA! and! ALA)! in! cord! blood! than! in! maternal! circulation52–54.! The! effect! by! which! the!percentages! of! FAs! are! found! to! be! higher! in! cord! blood! than! in! maternal! one! is! called!“biomagnification”.! Because! of! delta! 5F! and! delta! 6Fdesaturase! activities! in! fetal! liver!microsomes!are!very!low!and!because!no!activity!has!been!found!in!placenta55!a!preferential!and!selective!maternoFfetal!transfer!of!LCFPUFAs,!supported!by! in&vitro!and! in&vivo!studies,!has!been!proposed.!Larqué!et&al.&studying,! in&vivo,! the!placental!transfer!of!13CFlabeled!FAs,!demonstrated!a!preferential!accretion!of!DHA!into!the!human!placenta!relative!to!the!other!FAs!investigated!(LA,!palmitic!and!oleic!acid)56.!This!result!is!in!line!with!previous!findings!
!!
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from!in&vitro!and!perfusion!studies!that!showed!higher!affinities!and!binding!capacities!of!PFFABpm! for! ARA! and! DHA! compared! to! ALA! and! oleic! acid57! and! a! preferential! placentar!uptake!and!transfer!of!DHA58,59.!In! complicated! pregnancies! alterations! in! placental! transfer! of! LCFPUFAs! have! been!described.!In!gestational!diabetes!mellitus!(GDM)!there!is!an!higher!placental!uptake!of!LCFPUFAs!but!the!transport!to!fetal!circulation!is!impaired!compared!to!normal!pregnancies,!as!a! consequence! cord! levels! of! LCFPUFAs! are! found! to!be! lower! than!maternal! ones! 60,61.! In!intraFuterine!growth!restricted!(IUGR)!pregnancies!decreased!ARA/LA!and!DHA/ALA!ratios!are! observed! in! fetal! compared!with!maternal! blood,! probably! because! of! the! changes! in!transport!occurring!in!relation!to!placental!insufficiency62.!! In!this!study!with!the!use!of!a!stable!isotope!natural!abundance!approach,!we!aimed!to!measure!the!percentage!of!endogenous!DHA!synthesis!during!pregnancy!and!to!evaluate!its!transfer!from!maternal!to!fetal!circulation.!This! approach! is! based! on! the! fact! that! it’s! possible! to! trace! a! specific! nutrient! if! it! has! a!natural! 13C! enrichment! significantly! different! both! from! the! one! introduced!with! the! diet!and!from!the!one!endogenously!synthesized.!DHA!derived! from!oils!of!biotechnological!origin!and!produced!by!singleFcell!organisms! is!characterized! by! a! 13C! enrichment! significantly! different! from! the! one! produced!endogenously!by!progressive!desaturation!and!elongation!of!ALA.!Supplementation! during! pregnancy!with! this! type! of! oil! changes! the!mean! enrichment! of!maternal!DHA.!The!most! the!maternal!DHA! 13C! enrichment! resembles! the! one! of! supplemented!DHA! the!lower! is! the! endogenous!DHA! synthesis.!The!higher! the! ability! of! the!pregnant!woman! to!produce! DHA! the! most! 13C! enrichment! will! be! close! to! the! one! measured! before!supplementation’s!start.!
!!
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AIM'OF'THE'STUDY'! The! aim! of! this! study!was! to! evaluate! the! feasibility! of!measuring! DHA! synthesis!during!pregnancy!using!the!“stable!isotope!natural!abundance”!approach.!!!
MATERIAL'AND'METHODS'!!
Study'population''Women!eligible!for!the!study!were!pregnant!women!at!20!weeks!of!gestation!before!starting!DHA!supplementation.!Twenty!women!were!supplemented!with!capsule!containing!DHA!of!biotechnological!origin!(Study!Group)!and!6!with!capsule!containing!DHA!of!fish!origin!(Control!Group).!!
Study'design'Blood! samples! that! had! been! collected! at! times! of! diagnostic! veniFpunctures! for!routine!care!were!used!with!up!to!5!samples!per!woman.!A!first!blood!sample,!defined!as!the!baseline! (T0)! was! collected! before! the! start! of! the! DHA! supplementation,! at! 22!weeks! of!gestation.!A!second!and!a!third!samples,!T1!and!T2,!were!collected!respectively!after!10!days!of!supplementation!and!at!the!30th!week!of!gestation.!At!the!time!of!delivery!blood!samples!were!also!collected!from!the!mother!and!from!the!umbilical!cord.!!
Samples'collection,'storage'and'analytical'methods'Blood!samples!were!drawn! in!EDTAFcontaining! tubes;!plasma!was!separated! from!the! red! blood! cells! after! centrifugation! at! 1300! x!g! for! 10!minutes! at! room! temperature.!Plasma!was!stored!in!tubes!containing!pyrogallol!as!antioxidant!at!F80°C!until!analysis.!!
Isolation'and'analysis'of'FAs'profile'of'plasma'PLs''Plasma!lipids!were!extracted!from!200!μL!of!plasma,!according!to!Folch!et&al.63,!after!the!addition!of!appropriate!internal!standards!for!each!lipid!class!containing!both!nonanoic!and!heptadecanoic!or!pentadecanoic!acid.!The!extracts!were!dried!under!nitrogen!at!37°C.!The! lipids! were! dissolved! in! 100! μL! of! chloroform/methanol! (2:1,! v/v)! and! applied! to! a!Silica! Gel! TLC! plate! (20x20).! The! TLC! plate! was! developed! with!heptane/diisopropylether/acetic!acid!(60/40/3,!v/v/v).!After!drying,!the!lipid!classes!were!visualized!by! spraying! the!TLC!plate!with!1,2Fdichlorofluorescein! and!detected!under!UVFlight.!The!spots!corresponding!to! the!different! lipid!classes!were! identified!by!comparison!
!!
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with!standards,!scraped!off!and!collected!in!glass!tubes.!Methylation!was!performed!with!3!mL!HCl/MeOH,! the! tubes,! after! flushing!with!nitrogen,!were! capped! and! incubated! for!60!min!at!100°C.!After!cooling,!HCl!was!neutralized!by!adding!3!mL!of!10%!K2CO3.!The!methyl!esters! were! extracted! with! 250! μL! of! hexane/BHT! (50! mg/L).! 1! μL! of! the! extract! was!analysed! by! using! a! gas! chromatograph! with! a! flame! ionization! detector! (HPF5890,!Amstelveen,! Olanda).! Separation! of!methylFesters!was! achieved! on! an! Omegawax! column!(30!m!x!0.25!mm!x!0.25µm!film!thickness,!Supelco,!Milano,!Italy).!Injections!were!performed!in!splitless!mode!at!an!injector!temperature!of!280°!C.!!FAs,! from! C8! to! C24! carbon! atom,! were! identified! by! comparing! retention! times! with!reference!standards!(NuFCheck!Prep,!Inc.,!Elysian,!MN).!Data!for!plasma!FAs!are!expressed!in!moles!percent!(mol%).!Samples!were!analysed!in!single.!!
13C'DHA'plasmatic'enrichment'and'percentage'of'DHA'endogenous'synthesis'The!13C!enrichment!of!DHA!methyl!ester!derived! from!plasmatic!PLs!was!analyzed!by! using! gas! chromatographFcombustion! interphase! isotope! ratio–mass! spectrometer!(Delta! Plus! XL;! Finningan! MAT,! Bremen,! Germany).! Separation! of! methylFesters! was!achieved! on! a! DB225! column! (30!m! x! 0.25!mm! x! 0.25!µm! film! thickness;! Agilent! J! &!W,!Folsom,! CA).! Injections! were! performed! in! splitless! mode! at! an! injector! temperature! of!!!250°! C.! The! 13C! enrichment! of! DHA! was! expressed! as! δ13C! values! relative! to! Pee! Dee!Belemnite!(PDB)!carbonate64.!
δ13C!was!calculated!by!the!use!of!this!formula:!!!!"C = [(!! !!) − 1] ∗ 1000!Where:!Rx!=!isotopic!ratio!of!the!sample!!Rs!=!isotopic!ratio!of!the!reference!standard.!The!defined!reference!standard!for!13C!has!been!PDB!with!13C:!12C!of!0.0112372.!To!determine!13C!values!relative!to!the!PDB!reference,!CO2!samples!with!a!known!δ13C!value!(F61.5079)!were!introduced!at!appropriate!time!points!during!chromatography.!!All!samples!were!analysed!in!duplicate.!!! !
!!
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!The!following!equation!was!used!to!calculate!the!percentage!of!DHA!endogenous!synthesis!at!T2!and!at!Tdelivery:!Percentage!DHA!endogenous!synthesis!= 100 − [(! − !/! − !) ∗ 100]!Where:!A=!δ13C!value!of!the!plasma!phospholipid!DHA!at!T2!or!Tdelivery!!B!=!δ13C!value!of!the!plasma!phospholipid!DHA!at!T0!C!=!δ13C!value!of!the!DHA!present!in!the!capsule!!
Capsule'13C'DHA'enrichment'and'oil'FAs'composition''The!oil!present!inside!the!capsule!was!analysed!both!for!13C!DHA!enrichment!and!for!its!composition!in!FAs.!100! μL! of! diluted! oil! (1:50! in! chloroform)! after! the! addition! of! appropriate! internal!standards!(nonanoic!and!pentadecanoic!acid)!were!extracted!according!to!Folch!et&al.63.!The!extracts!were!dried!under!nitrogen!at!37°C.!Methylation!was!performed!as!described!above!for! FAs! derived! from! plasma! PLs.! The! methyl! esters! were! extracted! with! 1! mL! of!hexane/BHT!(50!mg/L).!The!extract!was!analysed!as!previously!described!for!plasma!PLs!in!order! to! obtain! information! about! relative! amounts! of! FAs! present! in! the! oil! and! 13C!enrichment!of!DHA!methyl!ester.!!









Table!1! reports! clinical!data!about!pregnancy!of! the!15!women!studied!until!delivery!and!newborn! characteristics! at! birth.! All! women! had! a! normal! pregnancy,! no! cases! of! GDM!neither!of!IUGR!were!observed!in!the!two!study!groups.!!
' Study'Group' Control'Group' p1"Length!of!Gestation!(wks)! 39.48!±!1.23!(N=11)! 39.79!±!0.30!(N=2)! 0.923!Weight!Increment!between!T0!and!Tdelivery!(kg)! 10.33!±!2.23!(N=11)! 13.50!±!4.12!(N=4)! 0.212!Newborn!Birth!weight!(gr)! 3417!±!286!(N=9)! 3536!±!557!(N=4)! 0.825!Newborn!Birth!length!(cm)! 49.78!±!0.83!(N=9)! 50.25!±!2.06!(N=4)! 0.825!!
Table' 1:! Clinical! data! about! pregnancy! in! the! 15! women! studied! until! delivery! and! newborns!characteristics!at!birth.!1!By!MannFWhitney!U!test.!!!










DHA'of'fish'origin'C8! 1.09! 1.13!C10! 0.51! 0.65!C14! 10.56! 3.91!C16! 26.56! 17.07!C16:1nF7! 0.42! 4.80!C18! 1.09! 4.78!C18:1nF9! 13.62! 10.56!C18:2nF6! 1.50! 1.56!C18:3nF6! 0.36! 0.74!C18:3nF3! 0.16! 0.53!C20! 1.80! 0.69!C20:3nF6! 0.56! 0.41!C20:4nF6! 0.54! 3.77!C20:3nF3! 0.15! 0.16!C20:5nF3! 0! 7.09!C22! 0.17! 0.41!C22:4nF6! 0.15! 0.52!C22:6nF3! 40.33! 45.27!
'
Table'3:!Composition!in!FAs!of!the!two!oils.!!
Effect'of'DHA'supplementation'on'13C'DHA'plasmatic'enrichment'!As! expected! by! the! design! of! the! study,! 13C! DHA! plasmatic! enrichment! changed!significantly!in!the!study!group!during!the!course!of!the!time,!no!differences!were!observed!in!the!control!group.!!!
! T0'
δ13C'vs'PBD! T1'δ13C'vs'PBD! T2'δ13C'vs'PBD! TDelivery'δ13C'vs'PBD! p1"
Study'Group'
F28,06!±!1.49a!N=16! F25.29!±!2.52abc!N=15! F23.14!±!2.64bc!N=12! F22.50!±!1.73bc!N=9! 0.0001!
Control'Group'
F28,27!±!0.48!!N=6! F27.95!±!0.52!N=6! 27.25!±!0.21!N=4! F27.60!±!1.09!N=4! 0.127!!
Table'4:!Maternal!13C!DHA!plasmatic!enrichment!in!the!two!study!groups!measured!at!the!different!study!time!points.!1!By!Friedman’s! test!2Fway!ANOVA.!Means!with!different! superscripts!are! significantly!different!(p<0.005).!
!!
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Study!Group!(N=9)! F22.50!±!1.73! F23.17!±!2.37! 0.139!Control!Group!(N=4)! F27.60!±!1.09! F27.60!±!1.22! 1.000!!
Table'5:!Maternal!and!cord!13C!DHA!plasmatic!enrichment!in!the!two!study!groups!at!the!time!of!delivery.!1!By!Wilcoxon!Ranked!Test.!!
Percentage'of'DHA'endogenous'synthesis'In!the!study!group!the!percentage!of!DHA!endogenous!synthesis!at!T2!and!at!Tdelivery!were!54.7!±13.0%!and!53.1!±!11.0%,!respectively.!!!














C14! 0.71!±!0.33! 0.75!±!0.35! 0.64!±!0.19! 0.62!±!0.22! 0.257!
C16! 35.69!±!1.20a! 35.57!±!2.45ab! 35.90!±!1.46ab! 37.18!±!1.67b! 0.086!
C16:1nF7! 0.85!±!0.31! 0.82!±!0.33! 0.79!±!0.19! 0.94!±!0.34! 0.724!
C18! 9.54!±!1.50! 9.30!±!1.52! 8.78!±!1.16! 8.62!±!1.11! 0.763!
C18:1nF9! 8.53!±!1.19ab! 8.29!±!1.30b! 8.83!±!0.98ab! 9.54!±!0.94a! 0.012!
C18:2nF6! 19.97!±!2.99! 19.98!±!4.58! 20.28!±!2.14! 19.43!±!2.00! 0.615!
C20! 0.40!±!0.12! 0.39!±!0.14! 0.43!±!0.16! 0.41!±!0.16! 0.878!
C20:2nF6! 0.34±0.11! 0.36±0.11! 0.35!±0.08! 0.29!±0.14! 0.224!
C20:3nF6! 3.25!±!0.81! 3.22!±!0.79! 3.16!±!0.61! 3.21!±!0.69! 0.878!
C20:4nF6! 9.98!±1.81! 9.85!±1.69! 9.09!±1.29! 9.10!±1.53! 0.008!
C22! 0.73!±!0.24! 0.76!±!0.29! 0.85!±!0.24! 0.75!±!0.30! 0.687!
C22:4nF6! 0.31±!0.13a! 0.31!±!0.12abc! 0.28±!0.11bc! 0.27!±!0.12bc! 0.020!
C22:6nF3! 4.13!±!1.28! 4.79!±!1.27! 4.91!±!1.35! 4.54!±!0.81! 0.013!
C24! 0.51±0.20! 0.51!±0.23! 0.59!±0.19! 0.44!±0.24! 0.184!











C14! 0.62!±!0.22! 0.73!±!0.28! 0.256!
C16! 37.18!±!1.67! 36.13!±!1.77! 0.100!
C16:1nF7! 0.94!±!0.34! 1.16!±!0.67! 0.256!
C18! 8.62!±!1.11! 13.22!±!2.91! 0.001!
C18:1nF9! 9.54!±!0.94! 6.89!±!1.88! 0.001!
C18:2nF6! 19.43!±2.00! 6.41!±1.35! 0.001!
C20! 0.41!±!0.16! 0.66!±!0.19! 0.001!
C20:2nF6! 0.29!±!0.14! 0.28!±!0.19! 0.910!
C20:3nF6! 3.21!±0.69! 4.07!±1.42! 0.041!
C20:4nF6! 9.10!±1.53! 16.24!±2.61! 0.001!
C22! 0.75!±!0.30! 0.80!±!0.38! 0.730!
C22:4nF6! 0.27!±0.12! 0.72!±!0.30! 0.001!
C22:6nF3! 4.54!±0.81! 6.50±2.02! 0.009!
C24! 0.44!±!0.24! 0.77!±0.59! 0.053!




DISCUSSION!! The! first! aim! of! this! study! was! to! evaluate! the! feasibility! of! measuring! DHA!endogenous!synthesis!using!the!“stable!isotope!natural!abundance”!approach.!The!same!approach!was!used!by!our!research!group!to!measure!endogenous!ARA!and!DHA!synthesis!over!long!periods!in!preterm!infants!fed!formula!containing!LCFPUFAs14.!Our!results!demonstrate!that!this!method!can!also!be!used!in!pregnant!woman!following!nF3!LCFPUFAs!supplementation!with!200!mg/die!of!DHA!of!biotechnological!origin.!In!this!way!there!is!no!need!for!administering!highly!enriched!and!expensive!tracers!or!for!altering!the!diet,! moreover! the! recommended! daily! dose! of! DHA! for! pregnant! and! lacting! woman!resulted!adequate!for!study’s!purpose.!Analysis! of! DHA! enrichment! of! biotechnological! origin! was! found! to! be! different!both!from!the!one!endogenously!synthesized!and!from!the!one!introduced!by!the!diet,!acting!as!a!natural!tracer.!On!the!other!hand,!and!as!expected,!DHA!enrichment!of!fish!origin!was!comparable! to! the! values! of! DHA! derived! from! plasma! PLs! at! baseline! in! all! study!population.! As! a! consequence,! after! the! start! of! supplementation! with! nF3! LCFPUFAs,! 13C!DHA!enrichment!of!maternal!plasma!PLs!did!not!change! in!the!control!group,!while! in!the!study!group!values!measured!at!T2!and!Tdelivery!were!found!to!be!significantly!different!from!the!values!measured!at!T0.!The! percentage! of! endogenous! DHA! synthesis!was! calculated! at! T2! and! at! Tdelivery.!Calculation!was!not! feasible! at!T1!because! 13C!DHA!enrichment! in!plasma!PLs!has!not! yet!reached! equilibrium! (T0! and!T1!were! not! statistically! different).! The!mean! value! found! at!both!times!was!about!50±10%.!This!means!that!half!of!the!DHA!found!in!plasma!PLs!comes!from! de& novo! synthesis.! Nevertheless! this! value! might! be! a! little! overFestimated.! DHA!introduced! by! the! diet! and! the! one! derived! from! lipolysis! of! adipose! tissue! can! not! be!discriminated!from!the!one!endogenously!synthesized!since!their!13C!enrichment!should!not!differ.!! As! an! evidence! of! the!well! known!maternal! transfer! of! LCFPUFAs! across! placenta,!DHA! enrichment! of! cord! plasma! PLs! was! found! to! be! not! significantly! different! from!maternal!values,!in!both!the!study!groups.!To! test! if! plasma! PLs’! FAs! composition! changes! significantly! during! the! course! of!gestation! the!profile! at! T0,! T1,! T2! and!Tdelivery!were! compared!by! Friedman’s!ANOVA.!Oleic!acid! (C18:1nF9)! significantly! increased! during! gestation,! adrenic! acid! (C22:4nF6)! steadily!diminished!while!ARA!decreased!significantly!from!T1!to!T2.!These!findings!are!in!line!with!previous!data!by!Al!et&al.!who!studied!maternal!FAs!patterns!during!normal!pregnancy,!from!the!10th!to!the!40th!week!of!gestation52.!In!our!study!population!the!start!of!supplementation!with! nF3! LCFPUFAs! increased! the! relative! amount! of! DHA,! being! T0! and! T1! significantly!
!!
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different.! Al! et& al.! reported! that! DHA! increased! until! 18th! week! of! gestation! and! then!diminished,!since!women!were!not!supplemented!during!pregnancy!this!might!explain!our!different!findings.!Data! obtained! from! comparisons! between! maternal! and! cord! plasma! PLs’! Fas!compositions! are! in! agreement! with! literature! data53,54.! Percentages! of! saturated! FAs!(stearic!and!arachidic!acid,!lignoceric!acid!showed!only!a!tendency!to!significance)!and!LCFPUFAs!(ARA,!dihomoFgammaFlinolenic!acid,!C22:4nF6,!and!DHA)!were!found!to!be!higher!in!cord!samples,!the!opposite!was!observed!for!LA!and!C18:1nF9.!!!













PULMONARY'SURFACTANT'COMPONENTS''Pulmonary! surfactant! is! a! complex!mixture! that! consists! of! roughly! 90%!of! lipids!and!10%!of!proteins.!80F90%! of! the! whole! lipid! portion! is! represented! by! phospholipids! (PLs),! while!cholesterol!comprises!the!largest!amount!of!neutral!lipidsiv.!!Phosphatidylcholine! (PC)! makes! up! the! major! part! (70F80%)! of! the! PLs! and! generally!around! 50F60%! of! PC! molecules! contain! two! saturated! fattyFacyl! moieties! (DSPC).!DipalmitoylFPC!(DPPC)!is!the!main!type!of!DSPC68.!Though!DPPC!is!not!the!sole!component!of!surfactant!in!lowering!the!surface!tension,!it!is!the!major!surfaceFactive!component.!DPPC!alone!is!capable!of!generating!low!surface!tensions!approaching!values!of!about!0!mN/m69.!The!second!most!abundant!PL!in!surfactant!is!phosphatidylglycerol!(PG)!that!is!present!at!7F15%!of! the! total! PLs;! other! surfactant!minor!PLs! include!phosphatidylethanolamine! (PE),!sphingomyelin!(SM),!phosphatidylinositol!(PI),!and!phosphatidylserine!(PS)70.!The! precise! role! of! PG,! rather! than! PI,! are! not! completely! understood69! but! evidences!suggest!that!PG!may!play!an!important!role! in!regulating!innate!immunity!and!respiratory!syncytial!virus!infection71,72.!Other!minor!PLs!are!unlikely!to!have!surface!active!properties!and!speculations!suggest!possible!roles!in!metabolism!and!in!its!signalling!events69.!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!iv!Free!fatty!acids!and!glycerides!are!found!only!in!trace!amounts.!
!!
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Cholesterol,!the!most!abundant!of!neutral!lipids,!when!added!to!DPPC!alone!or!DPPC!and!PG,!increases! adsorbtion! rates69,! however,! when! present! in! improper! amounts,! it! has! been!associated!with!impaired!surface!activity73.!!
!!
Figure2.!Composition!of!pulmonary!surfactant!From!Agassandian!et&al.70!! The!four!surfactantFassociated!proteins!(SPs)!A,!B,!C,!and!D!constitute!the!remaining!10%! of! pulmonary! surfactant.! SPFA! and! SPFD! have! hydrophilic! structures! that! consist! of!large!macromolecular!assemblies!and!belong!to!the!family!of!collectins74!while!SPFB!and!SPFC!are!small!proteins!with!an!extremely!hydrophobic!nature.!All!of!these!proteins!participate!to! surfactant! functions! and! formation.! Thanks! to! protein! biochemistry! and! genetic!techniques!it!has!been!possible!to!identify!the!specific!roles!of!each!SP.!SPFA! has! been! the! first! of! the! SPs! to! be! purified75! and! analysed! for! its! primary!structure76.! SPFA!has! four!domains:! i)! an! amino! terminus,! ii)! a! collagenFlike!domain,! iii)! a!neck!region,!and!iv)!a!carbohydrate!recognition!domain.!SPFA,!once!secreted,! is!assembled!into!a! large!oligomer!of!18!monomers,! grouped! in! six! trimeric! subunits,!whose!alignment!pattern!resembles!that!of!a!“bunch!of!tulips”67.!!Thanks!to!a!carbohydrate!recognition!domain,!SPFA!recognizes!oligosaccharide!moieties!on!various! lung! pathogens,! thus! opsonizes! microorganisms,! enhances! their! uptake! by!phagocytes,! and! stimulates! the! production! of! free! oxygen! radicals77,78.! SPFA! also! inhibits!directly! the! proliferation! of! GramFnegative! bacteria! by! increasing! the! permeability! of! the!microbial!cell!membrane77.!!
!!
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!! SPFB!is!a!relatively!small!homodimeric!protein,!comprising!two!subFunits!held!together!by! a! disulphide! bond! and! it! is! found! to! be! closely! associated! with! surfactant! PLs.! It! is!expressed!in!a!cell!specific!manner!by!Type!I!and!Type!II!cells92.!SPFB!has!several!functions!primarily! related! to! surface! tension! reduction! and!metabolism!of! pulmonary! surfactant93.!When!added!to!mixture!of!surfactantFlike!PLs,!SPFB!greatly!enhances!their!surface!tensionFreducing! properties94,! facilitates! lipid! insertion! from! lipid! vesicles! into! the! airFliquid!monolayer95,96,!and!counteracts!the!inhibition!of!surfactant!function!due!to!plasmaFderived!proteins,!that!is!assumed!to!occur!under!conditions!of!alveolar!protein!leakage97.!!In!the!presence!of!calcium!and!PLs,!SPFB!also!interacts!with!SPFA!to!form!tubular!myelin!and!is!essential! for!the!genesis!of! lamellar!bodies98,!unique!organelles!of!Type!II!cells! in!which!intracellular!surfactant!is!stored.!!!
!!
Figure' 4.! Proteolytic!processing!of! SPFB!and!SPFC! into!mature! forms!and! their!interactions!with!PLs!bilayers.!SPFB!is!represented!as!a!monomeric!structure.!From!Whitsett!et&al.99!!Targeted! disruption! of! the! SPFB! gene! resulted! in! lethal! postnatal! respiratory! failure!associated!with!pulmonary!actelectasis100.!SPFB!−/−!mice!showed!a!normal!composition!in!surfactant!PLs!but!no!lamellar!bodies!and!tubular!myelin!were!detected.!The!phenotype!of!SPFB!deficient!mice,!with!a!marked!decrease!in!fully!processed!SPFC!and!an!accumulation!of!
!!
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the! proFprotein,! indicated! SPFB! critical! role! into! the! appropriate! processing! of! SPFC!precursor99–101.!Consistently!with!the!lung!epithelialFcell!specific!expression!of!SPFB,!abnormalities!observed!in! SPFB! −/−! mice! and! in! infants! with! hereditary! SPFB! deficiency! were! confined! to! the!respiratory!tract100.!!SPFC!is!one!of!the!most!hydrophobic!proteins!in!the!proteome99!and!it!is!expressed!only! in! Type! II! cells.! It! consists! in! a! very! regular! and! rigid! alphaFhelix! that! covers!approximately!two!thirds!of!its!sequence!and!a!NFterminal!domain!with!two!palmitolyated!cysteine! residues65,74.! SPFC! activities! largely! overlap! those! of! SPFB:! when! added! to! PLs!mixture!SPFC!enhances!the!spreading!and!stability!of!PLs!in!a!similar!but!less!active!manner!to! that! of! SPFB95,99.! SPFC! contributes! to! respiratory! homeostasis! and! it! may! also! play! a!fundamental!role! in!pulmonary! immunology,!both!during!acute! lung! infection!and!chronic!lung! disease102.! SPFC! −/−! mice! develop! a! severe! progressive! pulmonary! disorder! with!histologic! features! associated! with! emphysema,! monocytic! infiltrates,! epithelial! cell!dysplasia,! and! atypical! accumulations! of! intracellular! lipids! in! Type! II! cells! and! alveolar!macrophages103.!In! agreement! with! the! proposed! immunological! and! immunomodulatory! role! of! SPFC,! in!!!SPFC! knockout! mice! the! pulmonary! clearance! of! RSV! was! found! to! be! diminished! and!associated!with!increased!and!prolonged!inflammation104.!!
SURFACTANT'METABOLISM:'SYNTHESIS,'SECRETION'AND'CATABOLISM''The! secretion! and! reFutilization! cycle! of! surfactant! involves! a! number! of! complex!regulated!processes:!synthesis,!packaging!into!lamellar!bodies,!transport!and!secretion!into!the!alveolar!lining!fluid!and!finally!degradation!and!recycling!back!into!the!Type!II!cells.!Surfactant! components! are! synthesised! in! the! endoplasmatic! reticulum,! then!packaged! and! stored! in! the! form! of! tightly! packed! membranes! in! lysosome–related!organelles!called!lamellar!bodies.!!As!described!above,! surfactant!PLs!are!particularly! enriched! in! saturated! fatty! acids,!with!DSPC!being!the!most!abundant!and!important!component.!The!de&novo&synthesis!of&PC!occurs!by!the!cytidine!diphosphocholine!(or!Kennedy)!pathway,!the! predominant! one! in!most! tissues70.! It! is! a! pathway! of! three! reactions,! by!which! fatty!acids,!synthesised!de&novo&by!the!lungs,!are!incorporated!into!newly!synthesised!PC.!The!α!isoform! of! CTP:phosphocholine! cytylytransferase! (CCTα)! represents! the! rateFlimiting! and!rateFregulatory! enzyme! of! PC! synthesis! in!mammalian! cells105.! Initially,! PC! is! enriched! in!unsaturated! species,! but,! thanks! to! acyl! remodelling! and! selective! transport!mechanisms,!the! final! composition! of! active! functional! surfactant! can! be! achieved! inside! lamellar!
!!
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bodies106.! PL! transfer! proteins! mediate! surfactant! PLs! transport! from! endoplasmatic!reticulum! to! the! lamellar! bodies,! where! membrane! transporters! proteins,! like! the! ATPFbinding! cassette! (ABC)! transporter! A3! (ABCA3v),! finally! catalyse! the! transFmembrane!movement!of!PLs.!Hydrophobic! proteins! B! and! C! are! synthesised! in! the! endoplasmatic! reticulum! as! large!precursors,! then! they!are! transported! from!the! transFGolgi! to! the! lamellar!bodies! through!the! multivesicular! bodies.! Proteolytic! processing! of! the! proFproteins! to! their! respective!mature! peptides! occurs! in! an! acidic! compartment! distal! to! the! Golgi,! consistent! with!processing! in! the!multivescicular!bodies92.!Multivesicular!bodies!are!organelles!containing!numerous!internal!unilamellar!vesicles!and!are!believed!to!precede!the!final!assembly!and!storage!of!surfactant.!!









Type! II! cells! and! macrophages! represent! the! two! distinct! mechanisms! by! which!surfactant! is! cleared! from!the!airways,!both!of! them!contributes!equally115.!There!are! two!main! differences! in! these! mechanism:! i)! surfactant! internalized! by! macrophages! is!completely! catabolized,! while! surfactant! taken! up! by! type! II! cells! is! either! recycled! or!catabolised,! ii)! taken! up! mechanism! by! type! II! cells! is! more! selective! depending! on! the!presence!of!SPs!and!on!the!physical!structure!of!surfactant,!which!is!influenced!by!SPFD115.!
'












' Neonatal! pneumonia! represents! a! significant!health! concern! in!neonatal!medicine,!especially!in!developing!countries.!!In!2012!an!updated!systematic!analysis!reported!that!64%!of!children!who!died!in!the!first!5!years! of! their! life! died! of! infectious! causes,! and! pneumonia! was! the! leading! cause!representing!almost!20%!of!total!deaths!worldwide117.!Most!of!these!deaths!(>95%)!occur!in! developing! countries! since! pneumonia! is!more! common! and!more! likely! to! be! fatal! in!children! with! severe! malnutrition118.! In! the! developed! countries,! pneumonia! annual!incidence!is!estimated!to!be!33!per!10000!in!children!younger!than!five!years119!and!it!is!a!leading!cause!of!hospitalization!among!children!in!the!United!States120.!In! order! to! eradicate! infection! and! provide! an! adequate! support! of! gas! exchange,!administration! of! antibiotic! agents! and! mechanical! ventilation! represent! the! standard!therapy!for!severe!pneumonia.!Bacterial!pneumonia!in!newborn!babies!can!cause!problems!with!the!functioning!of!pulmonary!surfactant,!thus,!for!these!infants!breathing!can!be!very!difficult.!A! well! functioning! surfactant! system! is! essential! for! lung! stability,! a! good! respiratory!compliance!and!an!efficient!gas!exchange.!Surfactant!homeostasis!and!functions!depend!on!the!presence!and!the!relative!amounts!of!its!components.!A!lack!or!an!altered!amount!of!one!or!more!surfactant!components!can!have!dramatic!consequences.!Adult! patients! affected! by! ARDS! and! severe! pneumonia! requiring! mechanical!ventilation! show! a! decreased! respiratory! compliance! and! an! impaired! gas! exchange.! In!these!patients!a!marked! impairment! in! the!composition!and! in! the!biophysical! function!of!surfactant! have! been! documented121–129.! SPs! were! decreased123,126,127,! the! relative! PC!palmitic! acid! content! was! reduced121,128,! and! a! reduction! in! PG! or! PC! could! be! observed!throughout121–123,125,129.!These!reductions!were!generally!associated!with!an!increase!in!the!
!!
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relative! amounts! of!minor! lipids! such! as! phosphatidylinositol,! phosphatidylethanolamine,!phosphatidylserine,!and!sphingomyelin.!In! pediatric! patients! while! it’s! well! established! that! surfactant! deficiency! causes!respiratory! failure! in!newborns!with!RDS130,! the!reduced!pulmonary!compliance!observed!in!term!newborns!at!the!onset!of!pneumonia!still!does!not!have!a!clear!explanation.!!Understanding! of! SPs! changes! in! children! with! lung! infection! is! limited! and!sometimes!discordant.!Reduced!amounts!of!SPFA!have!been!found!in!infants!with!acute!viral!bronchiolitis,! including! forms!due! to!Respiratory! Syncytial!Virus! (RSV)131,132! and!bacterial!and!viral!pneumonia133.!Kerr!et&al.132!found!decreased!levels!of!SPFB!in!the!bronchoalveolar!lavage! fluid! (BALF)! of! children! with! severe! RSV! bronchiolitis,! while! Le! Vine! et& al.! found!concentrations! that! did! not! differ! from! controls! in! infants! with! bacterial! and! viral!pneumonia133.! Moreover,! a! recent! study! in! children! with! acute! lung! injury,! showed! no!change!in!either!BALF!SPFB!and!SPFA!concentrations134.!!!!!
AIM'OF'THE'STUDY'





Study'population''From! January! 2011! to! December! 2013! we! prospectively! recruited! 13! term!newborns!(37!to!41!weeks!gestational!age),!up!to!10!days!of!life!with!neonatal!pneumonia.!We!also!recruited!15!newborns!with!no! lung!disease!who!required!mechanical!ventilation!for! elective! surgery! or! neurological! impairment.! All! newborns! were! admitted! to! the!Neonatal!Intensive!Care!Units!of!the!University!of!Padua!or!of!the!Polytechnic!University!of!Marche,!Ancona,!Italy.!The!diagnosis!of!pneumonia!was!based!on!the!2008!CDC/NHSN!(Centers!for!Disease!Control! and! Prevention/National! Healthcare! Safety! Network)! criteria! for! pneumonia! in!infants!≤1!year!of! age.!These! criteria!are!basically! limited! to! clinically!defined!pneumonia!and!are:!i)!chest!xFray!showing!new!or!progressive!or!persistent!infiltrate,!consolidation!or!cavitation! or! pneumatoceles;! ii)! worsening! gas! exchange! (desaturation! or! rise! in! oxygen!requirement! or! rise! in! ventilation! demand);! iii)! at! least! 3! of! the! following:! temperature!instability!with!no!other! recognized! cause;! leucopenia! (<4000!WBC/mm3)!or! leucocytosis!(≥15000!WBC/mm3)!with! left! shift! (≥10%!band! cells);! new! onset! of! purulent! sputum,! or!change!in!character!of!sputum,!or!increased!respiratory!secretions,!or!increased!suctioning!requirements;! apnea,! tachypnea,! nasal! flaring! with! retraction! of! chest! wall! or! grunting;!wheezing,! rales! or! rhonchi;! cough;! bradycardia! (<100! beats/min)! or! tachycardia!(>170beats/min).! Diagnosis! of! bacterial! pneumonia! was! based! on! these! indirect! clinical!criteria!and!on!the!response!given!by!every!infant!to!the!antibiotic!therapy.!Inclusion! criteria! were:! respiratory! failure! (newborns! with! pneumonia)! requiring!mechanical! ventilation! with! a! FiO2>0.35,! a! Mean! Airway! Pressure>7! cm! H2O,! and! a!prediction!to!be!mechanically!ventilated!for!at!least!48!h.!Control!newborns!had!no!lung!disease!(no!clinical!and!laboratory!signs!of!infection,!normal!chest!x!ray,!FiO2<0.30)!but!required!mechanical!ventilation!as!a!result!of!major!surgery!or!neurological!impairment!leading!to!poor!airway!control.!Another!inclusion!criteria!for!both!groups!was!the!presence,!at!the!start!of!the!study,!of!an!arterial! line,! placed! for! invasive! arterial! blood! pressure!monitoring! and/or! arterial! blood!gas!analysis.!Exclusion! criteria! were:! i)! severe! congenital! malformations;! ii)! chromosomal!abnormalities;! iii)! exogenous!surfactant!administration! in! the! last!48!h!before! the!start!of!the!study.!
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The!study!protocol!was!approved!by!the!Local!Ethics!Committee!of!the!University!of!Padua! and! by! the! Ethics! Committee! of! the! Polytechnic! University! of!Marche,! and!written!informed!consent!was!obtained!from!both!parents.!










Isolation,'quantification,'and'enrichment'of'DSPC''DSPC!was!extracted!from!TAs!according!to!the!method!of!Bligh!and!Dyer142!after!the!addition! of! internal! standard! (pentadecanoylphosphatidylcholine).! The! lipid! extract! was!dried!under!nitrogen!at!37°!C!and!then!reacted!with!osmium!tetroxide.!Surfactant!DSPC!was!then! isolated! by! thin! layer! chromatography! using! a! mixture! of!cholorform/methanol/potassium! chloride/triethylammine! (40/12/33/8/24,! v/v/v/v/v).!After!drying!DSPC!spot!was!visualized!spraying!the!TLC!plate!with!1,2Fdichlorofluorescein!and!detected!under!UVFlight.! The! spot!was! scraped!off! and! collected! in! glass! tubes.!DSPC!fatty!acids!were!hydrolyzed!and!derivatized!by! incubation! for!60!min!at!100°C!with!3!mL!HCl/MeOH.!After!cooling,!HCl!was!neutralized!by!adding!3!mL!of!10%!K2CO3.!Methyl!esters!were! extracted! with! 250! μL! of! hexane.! To! quantify! the! amount! of! DSPC! the! extract! was!analysed! by! using! a! gas! chromatograph! with! a! flame! ionization! detector! (HPF5890,!Amstelveen,!Olanda)143.!The!same!extract!was!analyzed!by!gasFchromatographyFmassFspectrometry!(GCFMS,!6890N! F! 5973! inert,! Agilent! Technologies,! Milan,! Italy)! to! measure! UF13CFpalmitate!enrichment.! The! gas! chromatograph! was! coupled! with! a! quadrupole! mass! spectrometer!operating!in!electron!impact!ionization!mode.!The! results! were! expressed! as! mole! percent! excess! (MPE)! referring! to! a! calibration!curve137,144.!MPE!represents!the!increase!in!the!mole!percentage!of!each!palmitic!acid!(UF13CFpalmitate)! above! the! baseline! value! obtained! at! the! start! of! the! study! before! tracer’s!administration.!!!




Urea'determination'in'plasma'and'TAs'A! commercially! available! colorimetric! assay!was! used! to!measure! urea! in! plasma!and! in! TAs! to! normalize! SPFB,! SPFA,! DSPC! and! PLs! for! the! epithelial! lining! fluid! (ELF)!volume146.!!
Calculation'and'Statistics'SP!amounts!in!TAs!were!expressed!as!%!of!PL!or!as!concentrations!in!ELF146.!DSPC!t1/2! and! pool! size! were! calculated! as! reported! in! previous! studies! published! by! our!group137,144.! Briefly! after! conversion! of! the! enrichment,! measured! at! different! times,! into!tracer/trace!ratio!(TTR),!the!TTR!values!were!fitted!to!a!one!or!two!phase!exponential!decay!and!the!equation!was!used!to!calculate!DPPC!kinetics!parameters.!The!pool!size!in!which!the!tracer!distributed!was!calculated!on!the!basis!of!Fick!principle,!while!the!halfFlife!of!(UF13CFPA)!DPPC!was!calculated!from!TTR!decayvi.!!Data!are!presented!as!mean!±!SD!or!median!(IQR)!based!on!the!variable!distribution.!Comparisons!within!the!groups!were!assessed!by!Wilcoxon!signedFrank!test.!Comparisons!between! the! two! study! groups!were! assessed! by! Student! t! test! or!MannFWhitney! U! test,!according!to!the!variable!distribution.!Significance!was!set!at!p≤0.05.!Pearson’s!correlation!analysis!was!performed! to! test! the! association!between!SPFB! (%PL)! ratio,! SPFB!ELF,! SPFA!(%PL)!ratio!and!SPFA!ELF!measured!at!the!start!of!the!study,!with!the!OI!and!DSPC!t1/2.!Statistical! analysis! was! performed! using! PASW! Statistics! 18.0! for!Windows! (SPSS!Inc,!Chicago,!IL).!!!
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p1'ELF!DSPC!start!of!the!study!(mg/ml)! 1.90!(0.63F4.10)!(n=11)! 4.13!(1.11F5.76)!(n=14)! 0.286!ELF!PL!start!of!the!study!(mg/ml)! 3.21!(1.41F6.85)!(n=11)! 6.82!(2.25F10.46)!(n=14)! 0.193!ELF!SPFB!start!of!the!study!(µg/ml)! 22.53!(2.12F56.29)!(n=11)! 7.86!(3.16F23.07)!(n=14)! 0.367!ELF!SPFA!start!of!the!study!(µg/ml)! 16.99!(11.95F44.19)!(n=11)! 15.99!(11.34F41.48)!(n=14)! 0.815!SPFB!(%PL)!start!of!the!study! 0.99!(0.20F1.33)!(n=11)! 0.28!(0.03F0.58)!(n=14)! 0.029!SPFA!(%PL)!start!of!the!study! 0.59!(0.39F1.23)!(n=11)! 0.43(0.23F0.70)!(n=14)! 0.171!SPFB!(%PL)!preFextubation! 0.05!(0.02F0.10)!(n=11)! 0.06!(0.03F0.09)!(n=7)! 0.821!SPFA!(%PL)!preFextubation! 0.26!(0.13F0.50)!(n=11)! 0.40!(0.14F0.79)!(n=7)! 0.497!!




Figure'2:'Changes!in!SPFB!and!SPFA!in!the!two!study!groups.!Panel!a!and!c!refer!to!Pneumonia!group,!b!and!d!to!Control!group.!!In!patients!with!pneumonia!SPFB,!expressed!as!%!of!PL,!was!significantly!higher!at!the!start!of! the! study! compared! to! the! percentage! found! before! extubation! (Panel& a,! 0.99! (0.20F1.33)%! and! 0.05! (0.02F0.10)%! respectively,! p=0.003).! Similarly,! SPFA! (%PL)! ratio! was!higher! at! study! start! than! before! extubation! (Panel& c,! 0.59! (0.39F1.23)%! and! 0.26! (0.13F0.50)%!respectively,!p=0.050).!In! control! newborns,! from!whom! SPs! could! be! measured! at! least! two! times! (n=7),! SPFB!(%PL)!did!not!differ!during! the! study!period,! (Panel&b,! 0.23! (0.03F0.31)%!and!0.06! (0.03F0.09)%,!p=0.398)!nor!did!SPFA! (%PL)! (Panel&d,! 0.42! (0.23F0.62)%!and!0.40! (0.14F0.79)%,!p=0.866).!!DSPC!t1/2!was!significantly!shorter!in!the!pneumonia!group!(11.8!(5.5F19.8)!h)!than!in! the! control! group! (26.6! (19.3F63.6)! h)! (p=0.011).!Median!DSPC! pool! size!was! lower! in!newborns! with! pneumonia! compared! to! newborns! with! no! lung! disease! (10.6! (4.3F30.0)!and!36.0!(29.5F84.0)!mg/kg!body!weight,!p=0.031).!No!significant!correlations!were!found!between!SP!amounts!at!the!start!of!the!study!and!the!DSPC!t1/2,!pool!size!or!OI,!both!in!the!pneumonia!and!control!groups.!!!!
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DISCUSSION'! In!this!study!SPFB!and!SPFA!amounts!in!TAs!of!term!newborns!with!pneumonia!were!compared!with!those!of!newborns!with!healthy!lungs.!We!also!studied!the!SPs!profile!during!pneumonia!clinical!course,!from!the!peak!of!the!disease!until!the!clinical!improvement!and!extubation.!Few!studies!have!explored!changes! in!TA!surfactant!protein!concentrations!during!pneumonia!in!children!and!no!one!have!presented!data!corrected!for!TA!dilution!(%!of!PL!and!ELF)!and/or!have!related!the!TA!SPs!amounts!to!the!severity!of!respiratory!failure133,134.!Expressing!surfactant!protein!levels!as!%!of!PL,!we!found!that!in!patients!with!pneumonia,!SPFB!was! significantly! higher! than! in! controls! at! study! start! and! that! both! SPFB! and! SPFA!decreased,! as! pulmonary! function! improved.! Expressing! data! as! µg/ml! ELF,!we! found! no!significant!differences!between!pneumonia!and!control!patients,!although!the!levels!of!SPFB!tended!to!be!higher!and!those!of!DSPC!and!PL!tended!to!be!lower!at!the!start!of!the!study!in!the! pneumonia! group.! We! also! found! that! DSPC! was! turned! over! at! a! faster! rate! in!pneumonia!and!that!DSPC!pool!size!was!significantly!decreased!in!the!pneumonia!group.!Based! on! literature! data130,147,148,! we! expected! to! find! lower! levels! of! SPFB! at! the!onset! of! pneumonia! and! to! observe! increasing! SPFB! levels! during! recovery.! Despite! the!heterogenity!of!data,!we!were!instead!struck!by!finding!at!the!onset!of!pneumonia!an!excess!of!SPFB,!with!respect!to!PL.!It!is!possible!that!SPFB!excess!represents!“spent!surfactant”,!that!could!contribute!with!factors,!like!a!leak!of!plasma!proteins!in!the!alveolar!space125,!or!SPFC!deficiency102,!to!the!decreased!lung!compliance!observed!at!the!onset!of!the!pneumonia.!The!observed! SPFB! excess! could,! however,! be! explained! by! other! mechanisms! like! increased!secretion! of! SPFB,! a! slower! clearance! or! a! combination! of! these!mechanisms.! Finally! it! is!possible! that! the! excess! of! SPFB! may! reflect! an! accumulation! of! surfactant! subfractions!particularly!enriched!in!SPFB139.!The!decrease!of!the!SPFB!(%PL)!ratio!along!with!clinical!and!respiratory!improvements,!were!reasonably!related!with!a!better!oxygenation!status,!which!may! represent! the! result! of! an! improved! clearance! or! a! decreased! secretion! of! SPFB.! Our!data!are!in!line!with!previous!results!obtained!both!in!animal!studies149,150!and!in!newborns!after! lung! injury151,152.! Ikegami! et& al.! found! that! in! healthy! mice! (with! normal! lungs)! the!induction!of!lung!injury!by!the!intraFtracheal!injection!of!LPS!resulted!in!an!increase!of!DSPC!and! SPFB,! mediated! by! STATF3,! which! is! consistent! with! an! acute! response! to! the! lung!injury149.!Moreover,!our!research!group!observed!how,!in!a!murine!model!of!unilateral!lung!injury,!DSPCFpalmitate!synthesis!was!faster!both!in!the!injured!and!in!the!nonFinjured!lungs,!compared!to!the!naïve!control!lungs.!In!this!way!we!proved!that,!after!a!local!instillation!of!acid! in! one! bronchus,! it! is! the! entire! lung! system! that! is! involved! in! responding! to! the!
!!
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damage!and!not!only!a!local!area!of!the!lung150.!Other!mechanisms!may!have!contributed!to!the!elevation!of!SPFB!levels.!Increased!expression!of!SPs!has!been!observed!both!in!animals!exposed!to!high!levels!of!inspired!oxygen153!and!in!mechanically!ventilated!ones154,!however!we!hypothesized!that!a!main!role!could!have!been!played!by!the!infection!and!be!mediated!by!STATF3!pathway.!A!study!performed!by!Epaud!et&al.!found!that!elevated!levels!of!mature!SPFB!peptide!in!the!airspaces!of!transgenic!mice!were!associated!with!decreased!inflammation!following!exposure! to! endotoxins155.! Based! on! these! findings! a! larger! study! could! help! us! to!understand!if,!in!term!newborns!with!pneumonia,!higher!levels!of!SPFB!are!associated!with!a!better!clinical!outcome!and!a!faster!recovery.!The! decreased! SPFA! (%PL)! ratio! during! resolution! of! pneumonia! could! be! related!either!to!differences!in!the!turnover!of!surfactant!or!to!other!phenomena!related!to!the!nonFrespiratory!properties!of!SPFA.!Only!two!reports!have!previously!described!surfactant!composition!changes!during!bacterial!pneumonia!in!infants133,134.!Both!studies!corrected!the!tracheal!aspirate!dilution!by!TA! total!protein! amount;! this!method! is! less! reliable! than! the!ELF!method!because!of! the!risk! to!underestimate! the!SPs!amounts!due! to! the! increased!alveolar!capillary! leak!during!the!disease’s!course156.!Kerr!et&al.132!measured!SP!levels!in!infants!ventilated!for!respiratory!failure!resulting!from!severe!RSV!bronchiolitis!but!tracheal!aspirate!dilution!was,!also!in!this!case,!corrected!by!TA!total!protein!amount.!In!our!study!we!used!urea!to!correct!for!surfactant!dilution146!in!the!first!TA!sample,!and! we! expressed! SP! concentrations! as! percentage! by! weight! of! total! PLs! in! absence! of!available!plasmatic!urea!level!in!the!second!TA.!At!the!end!of!the!study,!after!the!removal!of!the! arterial! line,! we! could! not! express! SP! as! ELF,! because! ethical! concerns! precluded!invasive! and! unnecessary! procedures,! such! as! the! collection! of! plasma! to! correct! for!surfactant!dilution.!We!therefore!chose!to!express!SPs!values!as!%!of!PL!because!the!amount!of! total!PL!recovered! from!TAs!did!not!significantly!differ! from!the!start! to! the!end!of! the!study!both! in! the!pneumonia!and! in! the! control!groups! (pneumonia:!0.14! (0.07F0.25)!and!0.17! (0.09F0.97)!mg/ml,! p=0.110;! controls:! 0.50! (0.20F0.75)! and! 0.39! (0.06F0.56)!mg/ml,!p=0.237).! This! implied! that! they! did! not! affect! the! SPs! (%PL)! ratio! and! they! did! not!introduce!a!bias!in!the!comparison!within!the!study!groups.!A!previous!study!performed!in!adults!with!pneumonia,!ARDS!or!cardiogenic!edema!showed!that!in!adults!with!pneumonia!the!BALF!PLs!and!PC!content!were!not!significantly!different!compared!to!controls125.! It! is!conceivable! that! the! TAs! unsaturatedFPC! derived! from! inflammatory! cells! may! have!contributed! to! maintain! the! same! amount! of! TAs! PL! content! in! our! newborns! with!
!!
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Lung'development''Human! lung! formation! is! divided! into! five! distinct! periods! on! the! basis! of! the!anatomic!changes!that!occur!in!lung!architecture:!the!embryonic,!the!pseudoglandular,!the!canalicular,!the!saccular,!and!the!alveolar!period157.!The! morphogenesis! of! the! lung! begins! from! the! anterior! foregut! endoderm.! During! the!embryonic! and! pseudoglandular! stages,! the! two! lung! buds! undergo! a! highly! regulated!branching! process! called! “branching&morphogenesis”! crucial! for! generating! the! structural!airways!as!well!as!the!terminal!alveolar!compartments!in!which!gas!exchange!occurs158.!During! the! canalicular! period,! that! goes! from! the! 16th! to! the! 26th! week! of! gestation,! the!respiratory!epithelium!begins!to!differentiate!and!surfactant!components!are!first!observed.!The!following!stage!is!the!saccular!one!and!encompasses!period!from!26!weeks!until!term,!which!is!considered!at!37!weeks!of!gestation.!Continued!proliferation!and!expansion!of!the!acinar!tubules,!decreased!prominence!of!the!interstitial!tissue!and!a!marked!thinning!of!the!airspace!walls!characterise!this!period157,159.!In!humans!the!formation!of!the!highly!septated!and!alveolarized!structures,! comprising! the!extensive!alveolar!surfaces!mediating!efficient!gas! exchange,! occurs! during! the! alveolar! stage! that! takes! place! from! late! gestation! to! the!postnatal!period160,161.!Immediately! after! birth,! lungs! are! filled! with! inhaled! gases! and! the! survival! is!entirely!dependent!on!gas!exchange!provided!by!the!lung.!The!generation!of!a!normal!lung!structure!and!a!sufficient!amount!of!pulmonary!surfactant!are!of!critical!importance!in!the!perinatal!adaptation!to!air!breathing.!Abnormalities! in! lung! formation! associate! with! different! types! of! diseases!depending!on!the!timing!at!which!the!formation!was!disrupted.!TrachealFesophageal!atresia,!for! example,! is! observed! if! defects! in! lung! formation! occur! during! the! embryonic! period,!while!diaphragmatic!hernia!can!occur!because!of!defects!in!closure!of!the!diaphragm!during!the!pseudoglandular!period157.!
!!
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Despite!surfactant!secretion!starts!nearly!at!24!weeks!of!gestation,!usually!only!infants!born!after!the!end!of!the!35nd!week!have!adequate!amounts!of!surfactant!to!breath!normally.!In!preterm! infants! lung!morphogenesis! has! proceeded! normally! until! birth! but! in! untreated!newborns!the!survival!is!limited!by!the!lack!of!pulmonary!surfactant.!!
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The!aetiology!of!RDS!has!been!proposed!as!multifactorial!and/or!multigenic166,!the!primary!deficiency!of!a!functional!surfactant!system!may!be!associated!with!other!preFnatal!or!postFnatal!factors!affecting!both!surfactant!synthesis!and!activity.!!Antenatal!steroids!in!combination!with!postnatal!surfactant!remains!the!mainstay!of!prevention! and! therapy! for! RDS! in! preterm! infants167.! Enhoring! and! Robertson! in! 1972!demonstrated! the! effectiveness! of! natural! lung! surfactant! administration! in! an! immature!rabbit! model! of! RDS168.! Systematic! reviews! of! randomized! controlled! trials! and! metaFanalyses! confirmed! that! exogenous! surfactant! treatment! in! preterm! newborns! with! RDS!reduces! mortality,! decreases! the! incidence! of! pulmonary! air! leak,! and! lowers! the! risk! of!chronic!lung!disease!or!death!at!28!days!of!age169,170.!The!rationale!of!surfactant!replacement!therapy!is!to!provide!surfactant!and!counterbalance!its!inactivation!or!inhibition!by!increasing!the!pool!size.!In!surfactant!replacement!therapy!exogenous! surfactant! is! given! at! doses! between! 10! and! 20! times! the! normal! pool! size! to!approximate!the!pool!size!of!term!infants171.!!Antenatal!steroids!are!administered!to!pregnant!woman!to!induce!lung!maturity!in!case!of!imminent! preterm! delivery,! because! of! their! effects! on! type! II! cells! differentiation! and!surfactant!production.!Clinical! data! support! evidence! from! animal! models! of! RDS! in! which! the! combination! of!antenatal! steroids! and! postnatal! surfactant! improves! lung! function! more! than! either!treatment!alone172–175.!!
Bronchopulmonary'dysplasia''BPD! is! defined! as! a! continuing! requirement! for! supplemental! oxygen! and/or!positive! pressure! ventilator! support! at! 36! weeks! of! postmenstrual! age176.! BPD! was!described!for!the!first!time!by!Northway,!in!1967,!as!a!chronic!lung!disease!in!late!preterm!infants,!caused!by!lung!injury!induced!by!mechanical!ventilation!and!oxygen!toxicity177.!After! the! 1990’s! with! the! availability! of! surfactant! treatments! and! the! general! use! of!antenatal! corticosteroids! that! further! increased! survival! of! extremely! low! birth! weight!infants,!BPD!became!the!major!pulmonary!complication!of!prematurity178.!Lungs!of!infants!suffering!of!BPD!are!now!characterized!by!less!fibrosis!and!inflammation!than!those!of!the!past!but!with!simplified!gas!exchange!structures.!Alveoli!are!fewer!and!larger!because!of!the!arrest!in!alveolar!and!vascular!development!occurred!at!the!time!of!delivery.!Thus,!oxygen!and!barotrauma!are!not!anymore!the!only!factors!initiating!much!of!the!lung!injury!in!very!preterm!infants.!
!!
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The! aetiology! of! BPD! is!multifactorial,! and! all! factors! occur! before! lung! development! has!completed.! Prenatal! and! postnatal! injuries! are! represented,! respectively,! by! exposure! to!intrauterine!infection!and!to!oxygen!and!mechanical!ventilation.!BPD!occurs!approximately!in!30%!of!infants!with!birth!weight!<!1000g!and!in!40%!of!those!born!at!less!than!28!weeks!of!gestation179!and!associates!with!longFterm!pulmonary!and/or!neurodevelopmental!disability!and!in!severe!cases!with!death178.!Despite!antenatal!steroids! reduced! the! incidence! of! RDS! they! have! not! significantly! decreased! BPD!incidence174,175.!There!are!no!pharmacological!treatments!available.!Despite!Vitamin!A,!caffeine!and!postnatal!corticosteroids!seem!to!reduce!BPD!the!only!way!to!decrease!the!severity!and!the!incidence! of! BPD! is! represented! by! the! use! of! CPAP! and! low! levels! of! supplemental!oxygen178.!!
Chorioamniositis'Chorioamnionitis! is! an! intrauterine! inflammation! of! the! fetal! membranes,! the!chorion! and! the! amnion.! It! can! be! divided! into! clinic! and! histological.! The! first! is!characterized! by!maternal! fever! and! a! systemic! inflammatory! response!while! the! second!shows!no!maternal!symptoms!and!can!be!diagnosed!only!by!histological!examination,!which!also!allows!classification!into!acute!or!chronic!chorioamnionitis.!The!acute!form!represents!the!acute!inflammatory!response!of!the!mother!and!the!fetus!to!extracellular!microorganisms!that!gain!access!to!the!gestational!sac.!Chorioamnionitis! is! an! important! cause! of! preterm! birth,! its! prevalence! is! inversely!proportional!to!gestational!age!and!affects!up!to!60%!of!extremely!low!preterm!infantsvii.!!Watterberg,!in!1996,!was!the!first!to!infer!the!existence!of!an!ambivalent!association!between! chorioamnionitis! and! respiratory! morbidity.! Infants! exposed! to! prenatal!inflammation!showed!a!lower!incidence!of!RDS!but!were!more!likely!to!develop!BPD180.!After! these! observations! many! research! groups! conducted! cohort! studies! on! respiratory!outcome!in!preterm!newborns,!exposed!and!not!exposed!to!histological!chorioamnionitis,!to!evaluate!incidence!of!RDS!and!BPD.!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!vii!Preterm!births!can!be!classified!according!to!gestational!age:!extreme!prematurity!(GA<!28!weeks),!severe!prematurity! (28<GA<!31!weeks),!moderate!prematurity! (31<GA<!32!weeks),!and!near! term!(34<GA<!36!weeks).!!Birth!weight! is! another!parameter!used! to! classify!newborns! into! two!groups:! extremely! low!birth!weight!infants!BW!<!1000!g!and!very!low!birth!weight!infants!BW!<!1500!g!Most!extremely!low!birth!weight!infants!are!also!the!youngest!of!premature!newborns,!usually!born!at!27!weeks!of!gestational!age!or!younger.!!
!!
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Clinical!and!experimental!data!from!humans!and!animals!agree!on!the!fact!that!exposure!to!intraFamniotic! inflammation! reduces! incidence! of! RDS181–183.! Lung! maturation! and!surfactant! synthesis!are! likely! to!be!mediated!by! increased! levels!of! interleukineF1!and!of!other!proFinflammatory!cytokines184–187.!However,!correlation!between!intraFamniotic!inflammation!and!BPD!is!more!controversial.!Chorioamnionitis!has!been!considered!essential! for!BPD!development!because! it! increases!the! likelihood! of! very! premature! birth! which! represents! the! single! most! important! risk!factor!for!the!disease188.!!!
AIM'OF'THE'STUDY''





Study'population'We!retrospectively!studied!preterm!newborns!affected!by!RDS!who!were!admitted!to! the!Neonatal! Intensive!Care!Units! of! the!Department! of! Pediatrics,!University! of! Padua!and!of!the!Division!of!Neonatology!“G.!Salesi”!Children’s!Hospital,!Ancona.!Eligible! infants! were! preterm! newborns! (24! to! 32! weeks! completed! gestation)! with!postnatal!age!of!24!hr!or!less!and!diagnosis!of!RDS.!Histological!chorioamnionitis!was!diagnosed!by!histological!examination!of!the!placenta!and!fetal!membranes.!BPD!was!assessed!at!36!weeks!of!postmenstrual!age!and!was!defined!as!the!requirement!for!supplemental!oxygen!and/or!positive!pressure!ventilator!support.!Inclusion!criteria!were:!i)!PaO2!<50mmHg!at!ambient!oxygen!ii)!central!cyanosis!at!ambient!oxygen!and!need!of!supplemental!oxygen!to!maintain!a!PaO2!!>50mmHg,!iii)!a!chest!radiography!with!diffuse!reticulogranular!appearance.!Exclusion!criteria!were:!i)!severe!congenital!malformations;!ii)!chromosomal!abnormalities;!iii)! exogenous! surfactant! administration! before! collection! of! TAs,! iv)! lack! of! histological!examination!report.!The!study!protocol!was!approved!by!the!Local!Ethics!Committee!of!the!University!of!Padua! and! by! the! Ethics! Committee! of! the! Polytechnic! University! of!Marche,! and!written!informed!consent!was!obtained!from!both!parents.!!





Quantification'of'surfactant'components'Quantification! of! SPFA,! SPFB,! DPSC,! PLs,! and! urea! were! performed! as! detailed!reported!in!Chapter!4.!Tot! PP! in! TAs!were! assayed! according! to! the!method! of! Lowry189.! Tot! PP! amount!was!calculated!from!a!standard!calibration!curve!from!0!to!32!µg!of!BSA.!Pulmonary! neutrophils! sequestration! was! quantified! by! measurement! of! MPO!activity.!Briefly,!100!µL!of!TAs!were!added!to!2.9!mL!of!a!50!mM!phosphate!buffer!(pH!6.0)!containing! 0.53! mM! OFdianisidine! hydrochloride! and! 0.0005%! hydrogen! peroxide.! MPO!activity!was! followed! spectrophotometrically! at! 25°! C! at! a!wavelength! of! 460! nm190.! One!unit!of!MPO!activity!was!defined!as!that!degrading!1!mmol!of!hydrogen!peroxide!per!minute!at!25°!C.!!
Calculation'and'Statistics''DSPC,!PL,!Tot!PP!amounts!and!MPO!activity!in!TAs!were!expressed!as!concentrations!in!ELF146.!SPs!were!expressed!as!concentrations!in!ELF!146,!as!%!of!PLs,!and!as!%!of!DSPC.!!Data!are!presented!as!mean!±!SD!or!median!(IQR)!based!on!the!variable!distribution.!Pairwise! comparisons! between! the! study! groups!were! assessed! by!MannFWhitney!U! test.!Significance!was!set!at!p!<!0.05.!Spearmann’s!correlation!analysis!was!performed!to!test!the!association!between!the!amount!of!each!surfactant!component!and!respiratory!parameters!at!study!start,!total!amount!of!surfactant!received!and!mechanical!ventilation!length.!Statistical! analysis! was! performed! using! PASW! Statistics! 18.0! for!Windows! (SPSS!Inc,!Chicago,!IL).!
!!
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RESULTS'! We!retrospectively!studied!46!preterm!newborns!affected!by!RDS.!These!newborns!fulfilled! the! inclusion! criteria! and! had! been! firstly! enrolled! for! surfactant! kinetic!studies191,192.!Nine! newborns! were! born! from! mothers! with! a! positive! diagnosis! of! histological!chorioamnionitis!(Chorio&+)!and!37!from!mothers!with!a!negative!diagnosis.!Sixteen!out!of!37! had! a! gestational! age! lower! than! 28!weeks! (GA≤28&Chorio& C),! 21! had! a! gestational! age!from!28!to!32!weeks!(28<GA≤32&Chorio&C).!!
!!
Figure'1.Pie!graph!of!study!groups.!!TAs!were!analyzed!to!quantify!DSPC,!PLs,!Tot!PP,!SPFA,!SPFB,!urea,!and!MPO!activity.!!Calculation!of!dilution!was!not!feasible!for!all!samples!because!of!the!lack!of!plasma!sample! or! because! of! a! high! dilution! of! the! TA! which! makes! the! correction! factor! not!reliable.!!In!Chorio&+! group!amounts!of! surfactant! components!were!expressed!as!ELF! in!6!out!of!9!TAs,!in!GA<28&Chorio&–!group!in!6!out!of!16,!and!in!28<GA<32&Chorio&–!group!in!13!out!of!21.!Since! PLs! quantification! is! not! reliable! when! amounts! of! PLs! are! too! scarce,! TAs! with! a!crude!value!of!DSPC!lower!than!0.01!mg/mL!were!not!analyzed!for!PLs!content.!! !
!!
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p1"Body!Weight!(grams)! 785!±!209! 789!±!184! 0.677!Gestational!Age!(wks)! 25.53!±!1.53! 26.13!±!1.28! 0.187!Age!at!TAs!collection!(hr)! 2.17![0.63F22.71]! 2.93![1.03F7.61]! 0.803!PCR! 4.02![2.90F24.15]! 2.90![2.90!F2.90]! 0.051!
PaO2! 50.25![37.27F53.14]! 43.17![36.69F45.80]! 0.181!
OI! 4.75![3.24F6.77]! 8.00![7.04F8.90]! 0.017!
MAP! 6.97![6.50F8.25]! 8.80![6.35F9.35]! 0.277!
FiO2! 0.29![0.21F0.50]! 0.45![0.35F0.50!]! 0.055!
AaDO2! 120.47![82.19F245.73]! 179.94![127.73F245.69]! 0.345!























p1'Body!Weight!(grams)! 789!±!184! 1157!±!340! 0.0001!Gestational!Age!(wks)! 26.13!±!1.28! 29.97!±!1.34! 0.0001!Age!at!TAs!collection!(hr)! 2.93![1.03F7.61]! 3.58[1.75F9.20]! 0.370!PCR! 2.90![2.90!F2.90]! 2.90![2.90F3.28]! 0.483!
PaO2! 43.17![36.69F45.80]! 43.17![39.80F68.80]! 0.332!
OI! 8.00[7.04F8.90]! 6.52![3.83F11.47]! 0.244!
MAP! 8.80![6.35F9.35]! 8.27![7.15F8.97]! 0.948!
FiO2! 0.45![0.35F0.50!]! 0.40[0.30F0.50]! 0.256!
AaDO2! 179.94![127.73F245.69]! 175.28![105.00F268.87]! 0.976!














ELF!DSPC!(mg/mL)! 0.64![0.29F4.59]! 0.75![0.42F1.03]! 0.831!ELF!Tot!PP!(mg/mL)! 30.01![26.00F41.17]! 16.12![11.02F22.77]! 0.007!ELF!SPFA!(µg/mL)! 27.28![10.01F54.93]! 17.49[7.91F37.60]! 0.831!ELF!SPFB!(µg/mL)! 5.57![3.36F10.64]! 4.87![2.91F7.70]! 0.579!ELF!MPO!!(mU/mL)! 1.51![0.55F246.30]! 1.98[0.78F75.78]! 0.701!SPFA%PL! 0.26![0.18F1.23]! 0.93[0.29F2.16]! 0.247!SPFA%DPSC! 2.82![0.77F5.77]! 3.21[1.05F6.79]! 0.899!SPFB%PL! 0.15![0.08F1.73]! 0.26![0.10F0.48]! 0.792!SPFB%DPSC! 0.83![0.18F1.93]! 0.68[0.21F1.29]! 0.705!!
Table'5.'Surfactant!composition!in!GA<28&Chorio&–!group!compared!to!that!of!
28<GA<32&Chorio&–.!
1'By!MannFWhitney!U!test!!As!expected!the!two!groups!differ!significantly!in!gestational!age!and!birth!weight.!Length!of!mechanical!ventilation!and!total!amount!of!surfactant! tended!to!be! lower! in! the!
28<GA<32&Chorio&–!group.!Tot! PP! were! found! to! be! significantly! higher! in! the! GA<28& Chorio& –! group! compared! to!





'! The! first!aim!of! this!study!was!to!evaluate! the!effect!of!exposition!to! inflammation!during! intraFuterine! life! on! surfactant! composition,! respiratory! status! at! birth! and!respiratory!outcome.!We! therefore! compared! preterm! newborns,! with! the! same! gestational! age,! born! from!mothers!with!positive!or!negative!diagnosis!of!histological!chorioamnionitis.!ELF!DSPC!tended!to!be!lower!in!GA<28&Chorio&–&than!in&Chorio&+!group.!No!differences!were!observed!in!SPs!and!Tot!PP!expressed!as!concentrations!in!ELF,!despite!the!median!value!of!SPFB! in! the!Chorio&+&group!was! almost! three! times! the! value! found! in! the&GA<28&Chorio&–!group.!To! the! best! of! our! knowledge! there! are! no! data! about! human! surfactant! composition! of!preterms! born! from! mothers! affected! by! histological! chorioamnionitis.! Several! animal!studies! investigated! the! effect! of! exposure! to! intrauterine! inflammation! on! lung! function!and!surfactant! composition184–186.! In! fetal! sheep! intraFamniotic!LPS! injection! increases! the!amount! of! SPs! recovered! from! BALF! after! birth! by! the! induction! of! SPs! mRNA184,! and!exposure! to! Ureaplasma! improves! lung! function! that! associated! with! an! increase! in!surfactant! lipids! as!well! in! the! expression! of! SPs!mRNA185.! In! a! study! performed! on! fetal!rabbits!intraFamniotic!administration!of!interleukinF1α!(ILF1!α)!was!found!to!increase!BALF!concentrations!of!SPs!and!DSPC186.!These!mechanisms! described! in! animals! studies! are! likely! to! explain! the! tendency! to! the!higher!amounts!of!ELF!DSPC!found!in!the!Chorio&+&group.!Based!on!the!effects!observed!in!animals!after!fetal!exposure!to!LPS184!and!in!animals!with!normal! lungs! after! LPS! intratracheal! injection149! we! expected! to! find! significantly! higher!amounts!of!SPFB!too.!The!lack!of!significance!in!SPs!concentration!is!likely!to!be!due!to!the!high!variance!of!ELF!SPFB!values!and!to!the!very!small!sample!size.!!ELF!SPFA!did!not!differ!between!the!two!study!groups,!the!significant!lower!value!found!in!the&GA<28&Chorio&–! group!when!expressed!as!percentage!of!DSPC! is! a! consequence!of! the!higher!levels!of!DSPC.!As!a!response!to! inflammation!exposure!during! intraFuterine! life,!newborns! from!mothers!with! histological! chorioamnionitis! tended! to! have!higher! plasmatic! levels! of! PCR! at! study!start.! The! significantly! higher! activity! of! MPO! measured! in! the! Chorio& +& TAs! is! due! to!neutrophils! entering! the! lung,! in! response! to! pulmonary! expression! of! proinflammatory!cytokines.!
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Finally,! in! line! with! literature! data! which! support! a! better! respiratory! status! both! in!animals181,182! and! human! newborns183,193! exposed! to! infection/inflammation! before! birth,!we! observed! significant! lower! values! of!OI! and! lower! doses! of! total! amount! of! surfactant!administered!in!the!Chorio&+&group!compared!to!those!of!GA<28&Chorio&–!group;!a!tendency!for!lower!values!of!FiO2!was!observed!too.!Despite! literature! data! suggest! also! higher! incidence! rates! of! BPD! in! infants! born! from!mothers! affected! by! histological! chorioamnionitis180,188,193,194,! in! our! study! cohort! no!differences!were!observed!in!the!incidence!of!BPD!at!36!weeks!of!postmenstrual!age.!The!second!aim!of!the!study!was!to!understand!the!role!played!by!gestational!age!on!surfactant!composition,!respiratory!status!at!birth!and!respiratory!outcome.!We! divided! newborns! from! mothers! with! a! negative! diagnosis! of! histological!chorioamnionitis!into!two!groups:!those!with!a!gestational!age!smaller!or!equal!to!28!weeks!and!those!with!a!gestational!age!comprised!between!28!and!32!weeks.!There! were! no! such! evident! differences! between! the! two! groups! both! in! surfactant!composition!and!in!respiratory!status.!The!only!significant!difference!was!represented!by!the!concentration!of!total!proteins!which!was! found! to! be! significantly! lower! in! 28<GA<32& Chorio& –! group.! The! higher! levels! of!proteins!found!in!TAs!of!the!GA<28&Chorio&–!group!suggest!an!alveolarFcapillary!membrane!more!permeable!and!a!more!massive!protein!leak.!!The!inactivation!of!surfactant,!due!to!physical!inhibitors,!it’s!likely!to!cause!the!tendency!in!higher!amounts!of!exogenous!surfactant!and!longer!mechanical!ventilation!required!by!the!
GA<28&Chorio&–!group!to!sustain!lung!function!and!mechanics.!In! the!Chorio&–!group!amounts!of!surfactant!received!and! length!of!mechanical!ventilation!were!found!to!correlate!significantly.!Another!significant,!but!negative,!correlation!was! found!between!ELF!SPFB!and!PaO2/FiO2,!the!worst!the!respiratory!status!the!higher!the!amount!of!SPFB!found!in!TAs.!This!finding!is!in! agreement!with! our! previous! study! performed! in! term! newborns! affected! by! neonatal!pneumonia!in!which!higher!levels!of!SPFB,!expressed!as!percentage!of!DSPC,!were!found!at!the!peak!of!the!disease.!Considering!the!surface!active!properties!of!SPFB!we!speculate!that!the! higher! amount! of! SPFB! could! represent! a! response! or! a! mechanism! of! the! lung! to!improve!gas!exchange.!In! the! Chorio& +& group! a! positive! correlation! was! observed! between! FiO2! and! the! total!amount!of!surfactant!received.!Our!study!has!two!major!limitations:!i)!the!small!sample!size!and!does!not!allow!to!highlight!differences! in! the! variables! considered! especially! in! presence! of! high! values! of! standard!deviation;!ii)!the!collection!of!samples!causes!a!dilution!which!is!of!particular!importance!in!
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newborns! affected! by! RDS,! because! of! the! high! final! dilution! amount! of! surfactant!components!can!not!be!expressed!as!ELF.!As! a! consequence,! in! order! to! confirm! these! findings! and! to! highlight! other! differences!among!study!groups!a!higher!number!of!infants!is!needed.!!!
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